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Opioid receptors (OR) are part of the class A of G-protein coupled receptors and the target
of the opiates, the most powerful analgesic molecules used in clinic. During a protracted
use, a tolerance to analgesic effect develops resulting in a reduction of the effectiveness.
So understanding mechanisms of tolerance is a great challenge and may help to find
new strategies to tackle this side effect. This review will summarize receptor-related
mechanisms that could underlie tolerance especially receptor desensitization. We will
focus on the latest data obtained on molecular mechanisms involved in opioid receptor
desensitization: phosphorylation, receptor uncoupling, internalization, and post-endocytic
fate of the receptor.
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INTRODUCTION
Opioids are the most potent drugs used for pain relief. However,
their therapeutic potential could be limited as a protracted use
will lead to tolerance to analgesic effects requiring escalating doses
that is associated with side effects such as respiratory depression.
A huge work has been devoted to decipher molecular mecha-
nisms of tolerance. It is now well-established that opioid receptors
(OR) desensitization and its molecular mechanisms are inti-
mately connected to this phenomenon. Since the beginning of
the 1980’s when the parallel between tolerance and desensitiza-
tion has been evoked, many studies came out on the molecular
mechanisms underlying OR desensitization. The number of pub-
lications related to OR desensitization increased dramatically
with the cloning of the opioid receptor 10 years later. In this
review, we made an effort to summarize a large amount of these
data and point out conflicting results by discussing about the
initial conditions (cell models, agonist treatments. . . ). We also
integrated the latest developments obtained on the role of recep-
tor trafficking in desensitization and tolerance and the concept of
biased agonism.
STRUCTURE AND FUNCTION OF OPIOID RECEPTORS
DIFFERENT TYPES OF OPIOID RECEPTOR
The idea that opiate narcotic analgesics must bind to specific
sites or opiate receptors, in the central nervous system and else-
where, in order to elicit pharmacological responses dates back
for half a century. It was based on the finding that there are
important structural and steric constraints on most of the actions
of opiates. Thus, Beckett and Casy (1954), and Portoghese (1965)
postulated the existence of multiple OR based on the relationship
between molecular structure of opiate drugs and their anal-
gesic activity. Opioid-binding sites in the central nervous system
were demonstrated in mammalian brain tissue in the 1970s by
using radioligand-binding assays on isolated brain tissue (Pert
and Snyder, 1973; Simon et al., 1973; Terenius, 1973), followed
by the characterization of endogenous opioid peptides (Hughes
et al., 1975; Cox et al., 1976; Guillemin et al., 1977; Goldstein
et al., 1981). The endogenous opioid system, whose involvement
in different physiological functions has been recently reviewed
(Bodnar, 2014), consists of four distinct neuronal systems that are
widely distributed throughout the CNS and peripheral organs. To
date, four OR have been cloned, the mu, kappa, delta and noci-
ceptin/orphanin FQ receptor (Evans et al., 1992; Kieffer et al.,
1992; Chen et al., 1993a,b; Meng et al., 1993; Thompson et al.,
1993; Fukuda et al., 1994; Mollereau et al., 1994). This latter,
despite its sequence homology with the first three ones, poorly
binds peptide and alkaloid opioid ligands (Mollereau et al., 1994;
Reinscheid et al., 1995). So, only data on mu (MOR), delta
(DOR), and kappa (KOR) OR will be included in this review.
The endogenous opioid peptides are generated from four precur-
sors: proopiomelanocortin, proenkephalin, prodynorphin, and
pronociceptin/orphanin FQ (Nakanishi et al., 1979; Kakidani
et al., 1982; Noda et al., 1982; Meunier et al., 1995; Reinscheid
et al., 1995), each generating biologically active peptides that are
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released at the synaptic terminals of opioidergic neurons. These
peptides exert their physiological actions by interacting with the
various classes of OR present on both pre- and post-synaptic
membranes of opioid and opioid target neurons (Besse et al.,
1990).
Receptor subtypes of mu, delta and kappa OR have been pro-
posed from the pharmacological in vitro and in vivo studies, but
at present there is no molecular evidence to account for a further
subclassification. Only one molecular entity for each receptor has
been cloned from a given species (Knapp et al., 1995; Dhawan
et al., 1996), although functional splice variants of MOR have
been discovered (Abbadie et al., 2004; Pasternak et al., 2004; Pan
et al., 2005; Pasternak and Pan, 2013). Recent explanations, not
mutually exclusives, regarding the diversity of pharmacological
responses following activation of a single target, have emerged
with the identification of OR heterodimers that appear to have
properties different from the monomeric receptors (Fujita et al.,
2014; Massotte, 2014; Ong and Cahill, 2014) and the notion of
biased agonism (see this review and Violin et al., 2014).
STRUCTURE
Opioid receptors belong to the class A of G protein-coupled
receptors (GPCR) which share some common features. They pos-
sess seven transmembrane domains linked by three intracellular
and three extracellular loops, an extracellular amino-terminus
and an intracytoplasmic C-terminus tail. The amino-terminus
region has putative glycosylation sites. Whereas O- and N-
glycosylation seems to be important for DOR maturation and
export to plasma membrane (Petaja-Repo et al., 2000), N-
glycosylation of MOR doesn’t affect its function (Befort et al.,
2001; Rostami et al., 2010). The transmembrane domains are
composed of a strong proportion of hydrophobic amino-acids
organized in alpha helix and demonstrate the highest sequence
homology between the three OR (around 70%) (Mollereau et al.,
1994). These domains contain cysteine residues that might be
important for ligand binding for MOR (Gioannini et al., 1999)
but not for DOR (Ehrlich et al., 1998). The three extracellu-
lar loops (most divergent in sequence), including the first two
ones linked by a disulfide bond would participate in ligand bind-
ing (Metzger and Ferguson, 1995). The three intracellular loops
would be more involved in G protein interaction (Metzger and
Ferguson, 1995; Georgoussi et al., 1997; Megaritis et al., 2000).
The carboxy-terminus tail has a low sequence homology between
the three OR. It contains putative phosphorylation sites (Ser, Thr,
and Tyr) involved in regulation events after ligand binding and a
conserved cysteine residue. This latter could be involved in recep-
tor palmitoylation, a reversible post-translational modification
that could regulate DOR surface expression for instance (Petaja-
Repo et al., 2006). However, in MOR, mutation of the two Cys
residues does not affect palmitoylation (Chen et al., 1998).
In the last few months, an important breakthrough has
been made with the crystal structures of MOR (Manglik et al.,
2012), DOR (Granier et al., 2012), and KOR (Wu et al., 2012)
at high resolution. The results obtained by these studies con-
firmed some previously discovered important characteristics of
OR. Pharmacology of OR has been described with the mes-
sage/address model: the ligand is composed of two parts, one
carrying the activity (agonist or antagonist) at the different
subtypes of OR, the “message” and one part, the “address,” con-
veying selectivity toward a given OR (Portoghese et al., 1990).
For the opioid peptides, enkephalins, dynorphins and endor-
phins, the N-terminal tyrosine residue may be considered as
the common message and the C-terminal domain presents the
variable address. The deep binding pocket responsible for the
“message” recognition is conserved between the different OR sub-
type, whereas the distal binding site responsible for the “address”
recognition is divergent (Metzger and Ferguson, 1995; Granier
et al., 2012; Manglik et al., 2012; Filizola and Devi, 2013). For
instance, the indole group of naltrindole, carrying the selectivity
toward DOR, interacts with the Leu7.35 residue. In theMOR, this
amino-acid is replaced by a Trp, preventing naltrindole binding
by steric hindrance (Granier et al., 2012; Manglik et al., 2012).
Interestingly, MOR crystallized in two-fold symmetrical dimer
(Manglik et al., 2012) whereas KOR (Wu et al., 2012) and DOR
(Granier et al., 2012) were also shown to adopt anti-parallel
arrangements. While those data reinforce the existence of OR
dimers (Massotte, 2014), one should keep in mind that the non-
physiological conditions (i.e., detergents and modified receptors)
used for such crystallographic studies could generate artifactual
interactions.
SIGNALING AND BIASED AGONISM
OR are mainly coupled to pertussis toxin-sensitive heterotrimeric
Gαi/o proteins and to a lesser extent to Gz (Law et al., 2000).
Gα and Gβγ dimer activate numerous intracellular effectors. The
most studied effector is the adenylyl cyclase (ACase) and investi-
gations on OR coupling demonstrated that stimulation of MOR,
DOR, and KOR in cellular models or ex vivo inhibited ACase
mainly via Gi/o proteins (Dhawan et al., 1996; Bian et al., 2012).
One of the fastest responses obtained after OR activation is the
regulation of certain types of ionic channels such as the inhibition
of voltage-dependent Ca2+ channels or activation of potassium
channels such as GIRK (G protein-coupled inwardly rectifying
K+ channels) (Law et al., 2000). Activation of K+ channels medi-
ates neuronal membrane hyperpolarization and reduces hyper-
excitability. The inhibition of voltage-dependent Ca2+ channel
blocks neurotransmitters release. These two phenomena partic-
ipate to reduce nociception mediated by OR. OR also activate
phospholipase C and mitogen-activated protein (MAP) kinases
pathways (Law et al., 2000).
Recently, a new notion has emerged from pharmacological
studies of GPCR, called biased agonism or functional selectiv-
ity. The binding of different ligands of a single receptor results in
distinct conformational changes of receptor; each conformation
preferentially interacts with selective partners producing specific
signaling cascades (Kenakin, 2011). One could trace back the first
data on biased agonism for OR when some authors demonstrated
that different ligands for the same OR activate different subsets
of Gαi/o proteins (Allouche et al., 1999a). Recently, Morse and
colleagues revealed a functional selectivity using a large panel
of opioid ligands by the label-free dynamic mass redistribution
technology which is based on the detection of refractive index
alterations measured by biosensor-coated microplates (Morse
et al., 2013); this suggests that opioid ligands are able to pro-
mote different conformational changes of OR. Many studies
have demonstrated the existence of a biased agonism for OR at
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different signaling events including desensitization, phosphory-
lation, endocytosis, trafficking, and in vivo effects (see below)
(Raehal et al., 2011; Pradhan et al., 2012; Kelly, 2013).
IN VIVO FUNCTION
The anatomical localization of OR in the brain and peripheral tis-
sues has been clearly established using autoradiographic methods
with selective radiolabeled ligands and detection of OR tran-
scripts using in situ hybridization (Mansour et al., 1995; Dhawan
et al., 1996). The different OR are widely distributed throughout
the central nervous system that explains the large pharmaco-
logical responses observed following administration of opioid
agonists.
The highest density of MOR is found in the caudate and puta-
men, where they exhibit a typical patchy distribution in the rat.
High levels of MOR are observed in the cortex, thalamus, nucleus
accumbens, hippocampus, and amygdala. Moderate levels are
found in the periaqueductal gray matter and raphe nuclei, and
low concentrations are seen in the hypothalamus, preoptic area,
and globus pallidus (Quirion et al., 1983). MOR are also present
in the superficial layers of the dorsal horn of the spinal cord (Besse
et al., 1990). This large distribution in both spinal and supraspinal
structures, as well as at periphery, shows thatMOR play an impor-
tant role in the control of nociception, in good agreement with the
pharmacological studies demonstrating that mu selective agonists
are potent antinociceptive drugs. Numerous other physiologi-
cal functions appear to be controlled by MOR. These include
reward, respiration, cardiovascular functions, bowel transit, feed-
ing, learning and memory, locomotor activity, thermoregulation,
hormone secretion, and immune functions (Dhawan et al., 1996;
Kieffer, 1999; Bodnar, 2014).
The distribution of KOR demonstrates some of the most strik-
ing species differences among the OR types. In the rat, they
represent only approximately 10% of the total number of OR,
while in most other species (guinea pig, monkey, and human)
they represent at least a third of the opioid binding popula-
tion (Dhawan et al., 1996). KOR have been found to be widely
distributed throughout the forebrain, midbrain, and brainstem.
They are implicated in the regulation of several functions, includ-
ing nociception, diuresis, mood, feeding, and neuroendocrine
secretions (Tejeda et al., 2012; Bodnar, 2014).
Compared toMOR and KOR, DOR aremore restricted in their
distribution and are densest in forebrain regions, well-conserved
across mammalian species. Dense binding is observed in the cau-
date, putamen, cerebral cortex, and amygdala, while they are
generally sparse to inexistent in thalamus and hypothalamus.
They play a role in different functions: nociception, locomotor
activity, gastro-intestinal motility, olfaction, cognitive function,
and mood driven behavior (Dhawan et al., 1996; Gaveriaux-Ruff
and Kieffer, 2002; Bodnar, 2014).
DESENSITIZATION
Chronic opioid use leads to tolerance, defined as a decrease of
the drug response. It’s possible to reproduce in vitro such phe-
nomenon when cellular models expressing OR are exposed to
agonists; in that situation, a decrease of signaling is observed
and is designated as OR desensitization. Some reports distinguish
the OR desensitization from the cellular tolerance. When rats are
chronically exposed to morphine, examination of MOR activity
on the outward potassium current shows a reduction compared
to naive animals which is not reversible even after 6 h in free-
morphine medium; this is cellular tolerance (Levitt andWilliams,
2012). In contrast, desensitization may be defined as a reduc-
tion of signal transduction from OR after acute activation by
agonists that recovers when cells or tissues are placed in agonist-
free medium. The first works studying the molecular mechanisms
underlying OR desensitization were reported more than 30 years
ago (Gahwiler, 1981; Law et al., 1982).
Initially, studying desensitization was made possible by using
experimental models endogenously expressing OR such as brain
membranes, rabbit cerebellum or cell lines (NG 108-15, SH-SY5Y,
SK-N-SH, SK-N-BE. . .). Since the cloning of the first OR, those
models have been superseded by heterologous expression systems
(HEK, CHO, COS-7, Xenopus laevis oocyte) in which OR are eas-
ily expressed in large amount but whose cellular characteristics
are far from neurons in which OR are endogenously expressed.
Desensitization of OR is studied on different signaling path-
ways including ACase inhibition, activation of MAP kinases, inhi-
bition of voltage-gated calcium channels and activation of GIRK
channels. Desensitization is sometimes evaluated by measuring
the ability of OR to activate G proteins in [35S]GTPγS binding
experiments after opioid agonists exposure. In absence of modifi-
cation on the downstream signaling pathway, G protein uncou-
pling is a good marker for desensitization but can’t be applied
for G protein-independent pathways (i.e., MAP kinases). The
comparison between desensitization studies suffers also from the
various experimental conditions used. Cellular model, agonist,
agonist concentration, time of exposure, level of OR expression
or signaling pathway studied are among the different parameters
that could influence OR desensitization as previously reviewed
(Connor et al., 2004).
DEFINITION
As indicated above, desensitization is defined as a progressive
reduction of signal transduction that occurs more or less rapidly
after OR activation depending on the agonist and the signaling
pathway. The rapid desensitization is mainly observed on the reg-
ulation of ion channel conductance from sec to several minutes
while a sustained desensitization is rather observed on regulation
of enzymes (ACase, MAP kinases) after minutes to several tens
of minutes. However, in this latter case, other counter-regulatory
mechanisms (internalization, traffic of OR) could participate
to desensitization making its description complex. Molecular
mechanisms turned out to be complicated for several reasons:
– A single OR can activate simultaneously different signaling
pathways such ACase, MAP kinases or ion channels and it
is possible to observe different levels of desensitization when
considering those cellular responses. For instance, we recently
showed that remifentanil, a MOR selective agonist, produces
a significant desensitization by 60% on the cAMP pathway
after 10min while at the same time desensitization of the MAP
kinases ERK1/2 signaling pathway was not significantly affected
(Nowoczyn et al., 2013).
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– Two types of desensitization, homologous and heterolo-
gous, were described. In homologous desensitization, only
agonist-activated receptors are desensitized while in heterolo-
gous desensitization, both agonist-activated and non-activated
receptors sharing the same signaling pathways are inactivated.
Those types of desensitization are related to different mech-
anisms especially in terms of receptor phosphorylation and
kinases (Chu et al., 2010). Cross-desensitization between OR
and other GPCRs is not systematically investigated and when
it is, the level of desensitization between GPCRs using the
same signaling pathway can be different (Namir et al., 1997).
Recently, Xu et al. showed a cross-desensitization between the
dopamine D1 receptors and DOR. This heterologous desen-
sitization characterized by an uncoupling of G proteins from
DOR is neither associated with modifications in receptor num-
ber nor in their phosphorylation but involves several kinases
[cAMP-dependent protein kinase (PKA), MAP kinases/ERK
kinase 1 (MEK1) and phosphoinositide-3 kinase (PI3K)] that
could phosphorylate signaling proteins (Xu et al., 2013).
– Desensitization results from several regulatory mechanisms
of signal transduction and depends on the number of active
receptors at the cell surface, the efficiency of OR/G proteins
coupling and the post-endocytic traffic. Recently, desensitiza-
tion of MOR expressed in the neurons from locus coeruleus
was demonstrated to result from a decrease of both number
of active receptors and the affinity of residual receptors for the
agonist (Williams, 2014).
This part will discuss recent data from literature regarding desen-
sitization of the different OR: the impact of the agonist used
through the notion of biased agonism, the role of phosphory-
lation and consequently the kinases involved, the implication of
arrestins and OR internalization and their fate after endocytosis.
Regarding MOR, a recent review has been published concerning
the molecular mechanisms involved in its regulation (Williams
et al., 2013).
EFFECT OF BIASED AGONISM ON OR DESENSITIZATION
The first reports describing a differential desensitization of MOR,
DOR, and KOR by various agonists came from Reisine’s group
(Blake et al., 1997a,b; Bot et al., 1997) suggesting that biased
agonism could influence desensitization; but at that time this con-
cept was not established yet. Few studies have been designed to
evaluate the impact of biased agonism on OR desensitization.
They would require determination of the relationship between
agonist concentration and the response from a large panel of
ligands. More generally, the comparison of the ability of two lig-
ands to promote OR desensitization is realized using the same
concentration regardless their intrinsic efficacy.
Biased agonism at MOR and desensitization
Functional studies revealed that [D-Ala2-MePhe4-Gly5-ol]
enkephalin (DAMGO) induced a stronger desensitization of
MOR than morphine in different experimental models and
signaling pathways (Yu et al., 1997; Whistler and Von Zastrow,
1998; Koch et al., 2001; Blanchet et al., 2003; Bailey et al.,
2009). However, such difference was not reported by others
(Liu and Prather, 2001; Borgland et al., 2003; Schulz et al.,
2004). In contrast, morphine was demonstrated to promote a
stronger MOR desensitization than DAMGO on the increase of
intracellular [Ca2+] (Chu et al., 2010). In another model, the
human neuroblastoma SH-SY5Y, it is possible to observe a huge
difference in MOR desensitization produced by morphine and
remifentanil on the cAMP pathway but not on the MAP kinases
ERK1/2 (Nowoczyn et al., 2013). All those discrepancies could be
due to the different level of OR expression, the cellular models
and the existence of spare receptors as previously mentioned
(Connor et al., 2004).
Biased agonism at DOR and desensitization
Evidence for a different DOR regulation by methadone and
morphine was also reported; a pretreatment with methadone
but not with morphine produced a cross-desensitization with
[D-Ala2, D-Leu5]-enkephalin (DADLE) and morphine (Liu
et al., 1999a). Similar data were reported by Bot et al. (1997).
In our laboratory, we also showed a differential regulation of
human DOR (hDOR) on both the inhibition of ACase and the
phosphorylation of ERK1/2 in the SK-N-BE cells. Initially, we
suggested that peptidic opioid agonists such as [D-Pen2-D-Pen5]-
enkephalin (DPDPE) and deltorphin I (H-Tyr-D-Ala-Phe-Asp-
Val-Val-Gly-NH2) induced a stronger and faster desensitization
compared to the alkaloid agonist etorphine (Allouche et al.,
1999b). However, using other peptidic ([Leu5]- and [Met5]-
enkephalins and UFP-512 ([H-Dmt-Tic-NH-CH(CH2-COOH)-
Bid])) and non-peptidic (SNC-80 ((+)-4-[(alpha R)-alpha-
((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-
N,N-diethyl-benzamide) and ARM-390) ligands we didn’t
confirm such assumption but our data rather suggest that DOR
selective agonists promote profound desensitization compared
to non-selective ligands (Marie et al., 2003a; Lecoq et al., 2004;
Aguila et al., 2007).
Biased agonism at KOR and desensitization
Very few studies examined the regulation of KOR by different
agonists. The group of Pei showed that desensitization of
KOR-mediated extracellular acidification response was greater
upon dynorphin A (1-13) stimulation than U69,593 ((+)-(5α,
7α,8β)-N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-
benzeneacetamide) and etorphine (Ling et al., 1998). On the
cAMP pathway, U50,488 (trans-(±)-3,4-Dichloro-N-methyl-N-
[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide) and dynorphin
A (1-17) produced a greater KOR desensitization than etorphine
or levorphanol (Blake et al., 1997b).
With respect to desensitization, all those data support the idea
that agonists are able to promote a different regulation of OR as
demonstrated for other GPCR such as the histamine H2 receptors
(Alonso et al., 2014). Such differential desensitization demon-
strated for each OR by different agonists is probably related to
the set of different regulatory molecular mechanisms (see above).
MECHANISMS OF OR DESENSITIZATION
OR phosphorylation
Numerous studies have been carried out to demonstrate the
role of OR phosphorylation in desensitization by using chemical
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inhibitors of kinases, in vitro or in vivo knock-out (KO) of kinases
using siRNA or transgenic mice, over-expression of dominant
negative mutants of kinases, amino acid substitution or trunca-
tion on OR. While in some studies the phosphorylation state of
OR is clearly determined, in most of them and especially those
using kinase inhibitors thismajor information is lacking. All those
data are summarized in Figures 1A–C.
MOR phosphorylation. Using metabolic labeling with [32P] and
different mutants at the C terminal tail, the group of Law demon-
strated that rat MOR (rMOR) displays a basal phosphorylation at
S363 and T370 and DAMGO increases phosphorylation at T370
and S375 (El Kouhen et al., 2001). Those results were recently
confirmed using specific antibodies directed against the phospho-
S363, phospho-T370 and phospho-S375 (Doll et al., 2011). As
demonstrated for the DOR (see below), agonist-induced MOR
phosphorylation is carried out hierarchically with first of all the
S375, considered as the major phosphorylation site, followed by
T370 (El Kouhen et al., 2001). Morphine was also shown to
increase S375 [or S377 for the human MOR (hMOR)] phospho-
rylation (Nowoczyn et al., 2013) but failed to phosphorylate T370
(Doll et al., 2011). Recently, Just and collaborators showed that
MOR is sequentially phosphorylated at S375, T370, T379, and
T376 by DAMGO. Interestingly, low concentrations of this opioid
agonist rather promote phosphorylation at S375 and T379 while
a strong phosphorylation of T370 and S375 is observed at higher
concentrations (Just et al., 2013).
Phosphorylation studies using liquid chromatography-mass
spectrometry techniques have led to the characterization of two
regions at the C terminal tail of the MOR (Lau et al., 2011):
the first region (amino acid 349–365) can be mono- or bi-
phosphorylated at S363 and in the cluster 354TSST357. While
the basal phosphorylation of S363 is not modified by ago-
nist exposure, morphine or DAMGO can increase phosphory-
lation at the cluster TSST. The second region 375STANT379 is
mono- or bi-phosphorylated upon agonist exposure. Rather than
qualitative differences, DAMGO and morphine were shown to
induce marked quantitatively different phosphorylation increase
in MOR. Using a similar experimental approach, two labora-
tories showed that rMOR and hMOR were phosphorylated in
the absence of agonist at S363 and T370 (Moulédous et al.,
2012; Chen et al., 2013). Moulédous et al. showed that DAMGO
increases hMOR phosphorylation at S356, T370, S375, and T376
(Moulédous et al., 2012) while Chen et al. compared the phospho-
rylation mediated by DAMGO andmorphine; these latter showed
that both agonists increase phosphorylation at S356, T357, T370,
and S375 (Chen et al., 2013).
Different kinases are involved inMOR phosphorylation. Using
siRNA against various forms of the G protein-coupled receptor
kinase (GRK) family, DAMGO was demonstrated to phospho-
rylate T370 and S375 by GRK2 and 3 while morphine increases
S375 phosphorylation by GRK5 (Doll et al., 2012). In SH-SY5Y
cells, hMOR phosphorylation at S377 (the equivalent of S375
for the rMOR) upon DAMGO exposure does not rely on GRK2
suggesting the implication of another kinases (Moulédous et al.,
2012). In vivo, using KO mice for either GRK3 or 5, morphine
rather promotes MOR phosphorylation at S375 by both kinases
FIGURE 1 | (A) Phosphorylation sites of MOR. The cluster 354TSST357:
phosphorylation both by DAMGO and morphine (Lau et al., 2011). The S356
(equivalent to Ser358 in human) is phosphorylated by DAMGO (Moulédous
et al., 2012), S356 and T357 are phosphorylated both by DAMGO and
morphine (Chen et al., 2013). The S363 (equivalent to S365 in human) is
phosphorylated in the absence of agonist (El Kouhen et al., 2001; Lau et al.,
2011; Moulédous et al., 2012; Chen et al., 2013). PKC was demonstrated to
phosphorylate S363 (Chen et al., 2013; Illing et al., 2014). The T370
(equivalent to T372 in human) is phosphorylated in the absence of agonist
(Continued)
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FIGURE 1 | Continued
(Moulédous et al., 2012; Chen et al., 2013). A decrease of phosphorylation
level is observed upon DAMGO and 1Dme (a neuropeptide FF analog)
exposure (Moulédous et al., 2012). PKC (Illing et al., 2014) and CaMKII
(Chen et al., 2013) phophorylate T370. DAMGO, morphine and etonitazene
increase phosphorylation at T370 (Doll et al., 2011; Lau et al., 2011).
DAMGO-mediated phosphorylation at this residue is ultra-rapid (20 s) (Just
et al., 2013) and involves GRK2 and 3 (Doll et al., 2012) but not PKC (Illing
et al., 2014). The cluster 375STANT379 displays higher level of
phosphorylation upon DAMGO compared to morphine (Lau et al., 2011).
S375 or T376 (equivalent to S377 and T378 in human) are phosphorylated
upon DAMGO and 1Dme (Moulédous et al., 2012), DAMGO, etonitazene,
and morphine (Doll et al., 2011). S375 is considered as the major
phosphorylation site as it is rapidly phosphorylated (20 s) upon DAMGO
(Just et al., 2013). This agonist-mediated phosphorylation does not
implicate PKC (Illing et al., 2014) but rather GRK2 (Chen et al., 2013) or
GRK2 and 3 (Doll et al., 2012) upon DAMGO exposure, and GRK5 and to a
lesser extent GRK3 upon morphine treatment (Doll et al., 2012). T376
(equivalent to T378 in human) is phosphorylated upon DAMGO and 1Dme
(Moulédous et al., 2012), by GRK2 and 3 upon DAMGO exposure but it is
considered as a late phosphorylation site (20min) (Just et al., 2013). T379 is
also phosphorylated upon DAMGO exposure after 1min and required the
GRK3 (Just et al., 2013). Y166 (Clayton et al., 2010) and Y336 (Zhang et al.,
2009) are phosphorylated by Src. (B) Phosphorylation sites of DOR. S344
phosphorylation is mediated by a PKC but is not increased by DPDPE
(Xiang et al., 2001). S358 and S363 (Guo et al., 2000; Kouhen et al., 2000)
are the two major sites of phosphorylation mediated by GRK2 upon DPDPE
exposure. Deltorphin II and morphine are also able to increase
phosphorylation at S363 (Navratilova et al., 2005). T361 is phosphorylated
by DPDPE but after S358 and S363 phosphorylation (Guo et al., 2000;
Kouhen et al., 2000). T161 is phosphorylated by CDK5 in the absence and
in the presence of chronic morphine exposure (Xie et al., 2009). Y318 is
phosphorylated by Src upon DTLET exposure (Kramer et al., 2000b). (C)
Phosphorylation sites of KOR. Phosphorylation of S369 (rKOR) is mediated
by GRK2 (Mclaughlin et al., 2003) and 3 (Mclaughlin et al., 2004) upon
U50488 exposure. In hKOR, S358 is phosphorylated by GRK2 when
activated by U50488 (Li et al., 2002).
while only GRK3 was required for fentanyl-induced MOR phos-
phorylation (Glück et al., 2014). Using the carboxy-terminal
region of MOR fused to glutathione S-transferase and puri-
fied kinases, PKC, GRK2, and calmodulin-dependent kinase II
(CaMKII) were shown to phosphorylate S363, S375 and T370,
respectively (Chen et al., 2013). Various PKC isoforms (PKCα, βII,
γ, ε) activated by phorbol 12-myristate 13-acetate (PMA) trig-
ger MOR phosphorylation at S363 and T370 but those kinases
are not recruited upon DAMGO stimulation (Doll et al., 2011;
Feng et al., 2011); those data indicate the role of PKC in the
basal and heterologous phosphorylation of MOR (Illing et al.,
2014).
The tyrosine kinase Src was also shown to phosphorylateMOR
at Y336, located in the NPXXY motif, after sustained morphine
treatment followed by naloxone (Zhang et al., 2009). The Y166,
located in the DRYmotif of the second intracellular loop ofMOR,
can be phosphorylated by Src but only upon co-activation with
DAMGO and epidermal growth factor (EGF) (Clayton et al.,
2010).
In summary, those studies revealed that S375 is the main phos-
phorylation site of MOR but agonists promote a differential and
a multi-phosphorylation of this OR as recently reviewed (Mann
et al., 2014).
DOR phosphorylation. Pei and colleagues were the first to
demonstrate that OR could be phosphorylated upon agonist
stimulation (Pei et al., 1995). They showed that DPDPE increases
incorporation of [32P] in a GRK-dependent manner. As shown
for MOR, the group of Law showed that DOR was sequentially
phosphorylated at S363, T358, and T361 upon DPDPE expo-
sure (Kouhen et al., 2000). Those results were confirmed by
another group who also demonstrated the critical role of GRK2
in DPDPE-induced phosphorylation of these residues (Guo et al.,
2000; Marie et al., 2008). Deltorphin II is also able to increase
S363 phosphorylation at hDOR but to a greater extent than mor-
phine (Navratilova et al., 2005). PKC can phosphorylate DOR
at S344 but is not required for DPDPE-induced DOR phos-
phorylation (Xiang et al., 2001). In a similar way as MOR,
DOR phosphorylation of the Y318, located in the NPXXY motif,
occurred upon DTLET ([D-Thr2-Leu5-Thr6]enkephalin) expo-
sure in a Src dependent manner (Kramer et al., 2000a,b). The
cyclin-dependent kinase 5 (Cdk5), a proline-directed S/T kinase,
was demonstrated to mediate basal andmorphine-activated DOR
phosphorylation at the T161 located in the second intracellular
loop (Xie et al., 2009).
KOR phosphorylation. Concerning KOR phosphorylation, the
data from literature are very scarce. The group of Chavkin showed
that rKOR is phosphorylated in vivo at S369 by GRK3 upon
U50,488 exposure (Mclaughlin et al., 2004) and in vitro by GRK2
(Mclaughlin et al., 2003). Upon global evaluation of the hKOR
phosphorylation, Li et al. observed that dynorphin A (1-17) and
U50,488 promote the highest phosphorylation, etorphine 50% of
the maximum and levorphanol failed to induce [32P] incorpora-
tion demonstrating that opioid agonists have different potencies
to phosphorylate this receptor (Li et al., 2003). It is noteworthy
that human and rodent KOR differ substantially in the amino
acid composition in the C-terminal region; such difference could
explain the absence of rKOR phosphorylation when activated by
U50,488 (Li et al., 2002). In hKOR, the S358, substituted by N
in the rKOR, is the major phosphorylation site mediated by the
GRK2 upon U50,488 exposure.
In summary, the phosphorylation sites for each OR were
mapped and showed that activation of a given receptor by dif-
ferent agonists results in a specific pattern involving different
kinases (Figures 1A–C). Those data are consistent with the model
of barcode established for the β-adrenergic receptor, a prototypic
GPCR (Nobles et al., 2011), and could determine the selective
interactions between the OR and partners such as arrestins.
Uncoupling between G proteins and OR
Any process interfering with the interaction between G proteins
and OR can lead to reduction of signal transduction intensity. G
protein uncoupling can be evidenced by binding studies on cel-
lular membranes using the radiolabeled non-hydrolyzable GTP
analog [35S]GTPγS which binds to a G protein activated by the
complex receptor-opioid agonist.
In CHO cells over-expressing hDOR, deltorphin II (H-Tyr-
D-Ala-Phe-Glu-Val-Val-Gly-NH2) pretreatment induces desen-
sitization after 30min on the ACase inhibition associated with
a G protein uncoupling (Navratilova et al., 2007). In the
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neuroblastoma×glioma (NG108-15) hybrid cells, morphine pre-
treatment failed to promote uncoupling of DOR from G proteins
while methadone did (Liu et al., 1999b). Conversely, after 5 days
of chronic morphine exposure, it is possible to observe a complete
uncoupling betweenMOR and its cognate G proteins (Bohn et al.,
2000). However, upon acute exposure (30min) morphine failed
to promote a reduction of [35S]GTPγS binding compared to
DAMGO indicating a great difference between agonists (Whistler
and Von Zastrow, 1998).When expressed in the CHO cell line, the
hKOR was demonstrated to undergo a time- and concentration-
dependent uncoupling from G proteins but with a moderate
impact on the inhibition of ACase (a two-fold increase of the EC50
value of the KOR agonist U50488) (Zhu et al., 1998).
Relationship between OR phosphorylation and desensitization
In most of these studies, the role of OR phosphorylation in
desensitization is indirectly demonstrated by using KO mice or
kinases chemical inhibitors; in such situations, we cannot rule
out the phosphorylation of other signaling proteins involved
in regulatory mechanisms of OR. Mutation of putative phos-
phorylation sites or truncation of the C terminal tail of OR
have been extensively used to delineate the role of phosphory-
lation in desensitization. All those data are summarized in the
Table 1.
MOR. Comparison between two truncated MOR in the C ter-
minal tail in HEK cells over-expressing a GRK2 peptide known
to block Gβγ-mediated recruitment of GRK at the plasma
membrane suggest that the amino acids sequence 354TSST357
plays a major role in GRK2-mediated MOR desensitization
upon DAMGO exposure (Wang, 2000). In locus coeruleus neu-
rons morphine induced MOR desensitization, measured on K+
current, in a PKC-dependent manner while GRK2 was required
for DAMGO-induced MOR desensitization (Bailey et al., 2009).
Such observations were confirmed by others on Ca2+ mobiliza-
tion; PKC-ε was required for morphine-induced MOR desensi-
tization but not upon etorphine, fentanyl and DAMGO (Zheng
et al., 2011). Recently, in locus coeruleus neurons and using
chemicals activators (phorbol-12,13-dibutyrate and phorbol-12-
myristate-13-acetate) or a muscarinic agonist known to activate
PKC, acute or sustained desensitization of MOR induced either
by morphine or [Met5]-enkephalin were demonstrated to differ-
entially required PKC activity but such effects were not inhib-
ited by the potent PKC inhibitor staurosporine (Arttamangkul
et al., 2014). Those data suggest that the involvement of PKC
in MOR desensitization would be cell-type specific. In the pres-
ence of DAMGO or [Met5]-enkephalin, the molecular mech-
anisms involved in MOR desensitization change during brain
development. In the locus coeruleus of young rats, those opi-
oid peptides produce heterologous MOR desensitization with
α2 adrenoreceptors in a GRK2-dependent manner but indepen-
dently of its kinase activity; the high GRK2 expression would
sequestrate Gβγ and interfere with K+ channels activation while
in mature rats, homologous MOR desensitization would be due
to receptor phosphorylation by this kinase (Llorente et al., 2012).
GRK2 was also shown to mediate heterologous desensitization
by promoting MOR transphosphorylation upon neuropeptide
FF receptor activation (Moulédous et al., 2012). The role of
phosphorylation in MOR desensitization has been challenged:
using staurosporine as a broad spectrum kinase inhibitor and a
GRK2-mutant mice, Arttamangkul et al. showed no modifica-
tion of [Met5]-enkephalin-induced receptor desensitization on
K+ channels in locus coeruleus neurons (Arttamangkul et al.,
2012).
Table 1 | Role of kinases in OR desensitization/tolerance.
OR Main results References
MOR GRK2-mediated desensitization after DAMGO exposure Wang, 2000
DAMGO mediates desensitization in a GRK2-dependent manner while morphine
induced-desensitization in a PKC-dependent fashion
Bailey et al., 2009
Role of PKCε in morphine- but not etorphine-, fentanyl-, and DAMGO-induced desensitization Zheng et al., 2011
Role of GRK2 in homologous and heterologous receptor desensitization Llorente et al., 2012
Role of GRK2 in heterologous desensitization between MOR and neuropeptide FF receptor Moulédous et al., 2012
No evidence for a role of GRK5 in the development of morphine tolerance Glück et al., 2014
Staurosporine and GRK inhibitors do not alter desensitization upon [Met5]-enkephalin exposure Arttamangkul et al., 2012
Role of PI3Kγ in desensitization and tolerance after chronic morphine treatment Konig et al., 2010
Role of JNK2 in tolerance and uncoupling after chronic morphine but not fentanyl treatment Melief et al., 2010
Role of Src in ACase superactivation after chronic morphine treatment and naloxone addition Zhang et al., 2009
DOR GRK2, PKC and a tyrosine kinase are involved in desensitization of hDOR when activated by etorphine Marie et al., 2008
Role of GRK6 in DPDPE-mediated desensitization Willets and Kelly, 2001
Role of PKC in DOR desensitization upon sustained activation by DADLE and [Leu5]-enkephalin Yoon et al., 1998; Song
and Chueh, 1999
Role of Src in DPDPE-induced DOR desensitization Archer-Lahlou et al., 2009;
Hong et al., 2009
KOR Expression of GRK3 or 5 alone is not sufficient to promote desensitization Appleyard et al., 1999
Role of GRK3 in development of U50,488 induced tolerance Mclaughlin et al., 2004
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The implication of other kinases than GRK and PKC in MOR
desensitization was also investigated. The PI3Kγ was demon-
strated to be involved in MOR desensitization on the inhibition
of voltage-gated calcium channels induced by chronic morphine
treatment (Konig et al., 2010). Using chemical inhibitor and KO
mice, c-Jun amino-terminal kinase 2 (JNK2) was demonstrated
to play a major role in morphine- but not fentanyl-induced G
protein uncoupling (Melief et al., 2010).
Some studies were also conducted to identify the amino acids
of MOR involved in desensitization. The T180A substitution
abolished MOR desensitization compared to wild type but the
phosphorylation state of the receptor was not evaluated (Celver
et al., 2004). The S375 was shown to play a major role in MOR
desensitization on the cAMP and MAP kinase pathways but only
when activated by morphine but not DAMGO (Schulz et al.,
2004). Activation of PKC by PMA but not DAMGO pretreat-
ment is able to promote MOR uncoupling from G proteins which
is attenuated by the S363A mutation (Feng et al., 2011); this
indicates that PKC-mediated phosphorylation of S363 as well as
T370 upon substance P receptor activation (Illing et al., 2014)
are potentially involved in heterologous desensitization. Using the
triple mutant (S363A, T370A, and S375A), Zheng et al. showed
that MOR desensitization upon etorphine, fentanyl and DAMGO
but not morphine was impaired indicating the different role of
amino acids phosphorylation in desensitization (Zheng et al.,
2011). As they also demonstrated that PKC mediated morphine-
induced MOR desensitization, it can be inferred that PKC would
phosphorylate MOR at other sites than S363, T370, and S375.
MOR desensitization and phosphorylation at S375 produced by
morphine can be modulated by other proteins such as the FK
binding protein 12 which would compete with kinase at MOR
(Yan et al., 2014).
While all those data indicate that MOR phosphorylation
would play a crucial role in desensitization, Qiu and collabora-
tors showed that a truncated mutant of MOR from S363 is able
to undergo a similar desensitization to the wild type demonstrat-
ing that receptor phosphorylation is not an absolute prerequisite
for desensitization (Qiu et al., 2003). However, phosphoryla-
tion would rather regulate MOR traffic which could indirectly
impact receptor desensitization (see Relationship between OR
Internalization and Desensitization).
DOR. In SK-N-BE cells, etorphine-induced hDOR desensitiza-
tion is totally inhibited by using the dominant negative GRK2
mutant K220R but is only reduced when using PKC and tyro-
sine kinase inhibitors (Marie et al., 2008). In the NG108-15 cell
line, rDOR desensitization promoted by a sustained treatment
with DPDPE is mediated by GRK6 but not GRK2 as indi-
cated above for hDOR (Willets and Kelly, 2001). The role of
PKC in DADLE- and [Leu5]-enkephalin-induced DOR desen-
sitization was also demonstrated on the mobilization of Ca2+
stores (Yoon et al., 1998; Song and Chueh, 1999). Tyrosine
kinases were also suggested to participate in DOR desensitization.
Genistein, a broad spectrum tyrosine kinase inhibitor, inhibits
hDOR desensitization promoted by DPDPE, deltorphin I, and
etorphine (Marie et al., 2008). Hong and collaborators found
that DPDPE promotes a tyrosine phosphorylation of DOR which
would recruit and activate Src that in turn could phosphorylate
and activate GRK2; this latter would then phosphorylates S363
and triggers desensitization (Hong et al., 2009). So, inhibition
of Src by PP2 reduces DPDPE-induced DOR phosphorylation
of S363 and desensitization on the cAMP pathway but via an
indirect mechanism. The role of Src in DOR regulation was
also confirmed by the group of Pineyro (Archer-Lahlou et al.,
2009).
The major role of DOR phosphorylation at S363 was con-
firmed using the mutant receptor S363A. While deltorphin II
promotes a rapid receptor phosphorylation at this amino acid
and desensitization on the cAMP pathway, this latter is totally
abolished in the S363A mutant (Navratilova et al., 2007). The
T161 of DOR, located in the second intracellular loop and equiv-
alent to the T180 of MOR, also plays a role in DPDPE-induced
desensitization; the substitution T161A severely impairs DOR
desensitization measured on GIRK channels (Lowe et al., 2002).
However, those authors did not evaluate the phosphorylation at
this residue. The importance of phosphorylation in DOR desen-
sitization was challenged by the work of Qiu and colleagues
who studies those processes using a DOR mutant in which all
Ser/Thr residues in the C-terminus region were mutated to Ala
(Qiu et al., 2007). They observed that DPDPE-induced desen-
sitization on the inhibition of ACase was significantly delayed
but not abolished. This indicates that other mechanisms than
phosphorylation could contribute to receptor desensitization.
KOR. In the Xenopus oocyte expression system, examination of
rKOR regulation on the activation of potassium channels revealed
that over-expression of GRK3 or 5 alone did not promote a sig-
nificant desensitization which requires both GRK and arrestin
3 (Appleyard et al., 1999). This was confirmed when rKOR and
GRK2 were co-expressed in CHO cells; pretreatment with a high
concentration of U50,488 failed to promote KOR uncoupling
from G proteins (Li et al., 2002). Truncation of the C terminal
tail of the receptor or the substitution S369A severely impaired
U69,593-induced desensitization. These data were further con-
firmed when wild type and mutant rKOR were expressed in
the pituitary adenoma cell line atT-20 cells (Mclaughlin et al.,
2003). As indicated above, S358 is the major phosphorylation
site for hKOR and the S358N substitution totally abolished
U50,488-induced receptor uncoupling from G proteins (Li et al.,
2002).
While most of those studies with either indirect or direct
proofs indicate the role of OR phosphorylation in desensiti-
zation, some of them clearly ruled out such paradigm. This
probably indicates that phosphorylation is not a prerequisite for
desensitization but would accelerate such process.
Role of arrestins in OR regulation
From the canonical model of GPCR regulation by Lefkowitz,
arrestins (arrestins 2 and 3 also named β-arrestins 1 and 2, respec-
tively) play a pivotal role in receptor regulation by promoting G
protein uncoupling and receptor endocytosis (Pierce et al., 2002).
As expected, those proteins were also demonstrated to regulate
OR functions. Indeed, over-expression of arrestin 2 induces a
selective uncoupling of DOR and KOR and reduces inhibition
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of ACase (Cheng et al., 1998). However, no significant impact
was observed for MOR explaining the lower desensitization rate
compared to DOR (Lowe et al., 2002). In recent studies using
BRET (Bioluminescence Resonance Energy Transfert) or FRET
(Fluorescence Resonance Energy Transfer) techniques, a large
panel of opioid ligands were shown to have a different ability to
both activate G proteins and recruit arrestins at MOR and DOR
(Mcpherson et al., 2010; Molinari et al., 2010; Rivero et al., 2012).
For instance, morphine was demonstrated to behave as a partial
agonist for DOR and MOR in G protein coupling experiments
while almost no interaction with arrestins was detected. This indi-
cates that all opioid ligands do not have the same potency to
promote OR desensitization.
Relationship between arrestins and OR desensitization. Genetic
ablation of arrestin 3 significantly reduces MOR uncoupling from
G proteins upon chronic morphine treatment (Bohn et al., 2000).
Using dorsal root ganglion neurons from arrestin 3 KO mice,
the role of this protein in mediating inhibitory regulation of
MOR by JNK on voltage-dependent calcium channels was evi-
denced (Mittal et al., 2012). This report suggests that arrestin
3 and not arrestin 2 would promote MOR desensitization by
interacting with JNK. However, in dorsal root ganglion neurons
obtained from arrestin 3 KO mice, acute MOR desensitization
elicited by DAMGO or morphine on the inhibition of voltage-
gated calcium channels was not significantly different from wild
type mice indicating that arrestin 3 has no major role in those
conditions (Walwyn et al., 2007). Similarly, in neurons from
locus coeruleus no significant role of arrestin 3 was evidenced
in acute MOR desensitization upon [Met5]-enkephalin exposure
on the activation of K+ currents (Dang et al., 2009). Yet, con-
comitant inhibition of arrestin 3 expression (arrestin 3 KO mice)
and ERK1/2 activity by PD98059 results in reduction of MOR
desensitization indicating that this process involves two inde-
pendent pathways. In the Xenopus oocyte, over-expression of
arrestin alone is not sufficient to increase DOR (Kovoor et al.,
1999) or KOR (Appleyard et al., 1999) desensitization while in
HEK cells, this over-expression enables morphine-induced MOR
desensitization probably by increasing both G protein uncou-
pling and receptor internalization (Whistler and Von Zastrow,
1998). However, such potentiation could be obtained either when
arrestin and a GRK are co-expressed or when the constitutive
active arrestin mutant R169E is present. This suggests that OR
phosphorylation is a pre-requisite for arrestin action. This con-
clusion is in good agreement with the data obtained by Johnson
et al. on MOR desensitization (Johnson et al., 2006). The translo-
cation of arrestin-2-GFP from cytosol to plasma membrane is
only observed upon DAMGO exposure which promotes MOR
phosphorylation by GRK2. In contrast, no such translocation
could be detected in morphine-treated cells which produce a
PKC-dependent MOR desensitization. The use of mouse embry-
onic fibroblast (MEF) from single or double KOmice for arrestins
2 and 3 revealed that DOR desensitization induced by DPDPE
relies predominantly on arrestin 3 expression suggesting a pref-
erential interaction between DOR and this arrestin isoform (Qiu
et al., 2007). In the SK-N-BE cells, DOR desensitization is reduced
when arrestin 2 expression is inhibited by shRNA only upon
DPDPE and deltorphin I exposure but not with etorphine (Aguila
et al., 2012).
All those data indicate that different mechanisms are respon-
sible for OR desensitization: some are arrestin-dependent and
requires GRK while others are arrestin-independent.
OR internalization
The number of active OR at the cell surface is regulated by
two processes: endocytosis and export of neosynthesized recep-
tors. Intuitively, when OR internalization is stimulated by agonist
exposure, one could expect a reduction in signal transduction.
However, the relationship between the number of OR and the
cellular response is not linear.
Internalization of OR has been demonstrated in different
models with different technical approaches but some discrep-
ancies have been reported. U50,488 and dynorphin A (1-17),
but neither etorphine nor levorphanol, promote a time-, and
concentration-dependent internalization of hKOR (Li et al.,
2003). In several reports, morphine was described as a poor
internalizing agonist of MOR in HEK cells (Keith et al., 1998;
Whistler and Von Zastrow, 1998; Schulz et al., 2004; Just et al.,
2013) but also in enteric neurons (Anselmi et al., 2013) and in
brain slice from transgenic mice expressing a FLAG-tagged MOR
(Arttamangkul et al., 2008). In few publications, MORwas shown
to internalize upon morphine exposure. This was demonstrated
for the endogenous MOR in striatal neurons (Haberstock-Debic
et al., 2005) and occurred mainly in dendrites (Haberstock-
Debic et al., 2003), in the human neuroblastoma cells SH-SY5Y
(Nowoczyn et al., 2013) and in double KO MEF for arrestins
transfected both with MOR and arrestin 3 (Groer et al., 2011);
in those latter publications, morphine-induced receptor inter-
nalization was observed for longer time treatment compared to
DAMGO. Using a quantitative assay, 30min morphine expo-
sure promotes half of the MOR internalization induced by
DAMGO (Mcpherson et al., 2010). In enteric neurons, mor-
phine promotes a weak internalization of MOR compared to
DAMGO as indicated above but chronic morphine exposure
results in a significant increase in endocytosis (Patierno et al.,
2011).
Role of OR phosphorylation in internalization
The role of OR phosphorylation in endocytosis was mainly inves-
tigated using ORmutants defective in phosphorylation. The trun-
cated MOR from S363, which is not phosphorylated by DAMGO
treatment, was shown to internalize but with a slower rate than
the wild type receptor during the first 30min (Qiu et al., 2003).
The S375A mutation strongly impairs DAMGO-driven MOR
endocytosis (Schulz et al., 2004). The T370A substitution has
no significant effect on DAMGO-induced MOR internalization
while it inhibits endocytosis triggered by PKC activation (Illing
et al., 2014). This suggests that PKC is able to phosphorylateMOR
at T370 and promotes its internalization. Conversely, the role
of PKC in internalization was ruled out using activators of this
kinase in the locus coeruleus neurons expressing the FLAG-tagged
MOR (Arttamangkul et al., 2014). Herkinorin, a MOR agonist,
is unable to promote both phosphorylation and internalization
indicating that the two processes could be linked (Groer et al.,
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2007). More than a selective phosphorylation on a specific residue
of the carboxy-terminal tail of the receptor, the level of MOR
internalization would be correlated to the multi-phosphorylation
of T370, S375, T376, and T379 (Just et al., 2013).
As demonstrated for MOR, the phosphorylation-deficient
DOR mutant (T358A/T361A/S363G) is able to undergo internal-
ization upon DPDPE activation but to a lesser extent than the
wild type (Zhang et al., 2005). However, this DORmutant cannot
internalize anymore when arrestin 3 expression is knocked-down
suggesting that the non-phosphorylated DOR can internalize but
in an arrestin 3-dependent manner. When the major site of phos-
phorylation of DOR is mutated (S363A), it is possible to observe a
deltorphin I-induced endocytosis (Navratilova et al., 2007); how-
ever, it is difficult to assume that this mutation has no impact on
internalization since no quantitative evaluation was made. This
is in contrast with the study of Bradbury et al. who observed a
close correlation between the ability of agonists to phosphorylate
the S363 and the degree of DOR internalization (Bradbury et al.,
2009).
Concerning the rKOR, the phosphorylation-defective mutant
S369E is unable to internalize upon U50,488 exposure demon-
strating the role of receptor phosphorylation in endocytosis
(Mclaughlin et al., 2003).
While those data indicate that MOR and DOR phospho-
rylation would favor their endocytosis, KOR phosphorylation
would be essential to promote its internalization. Other pro-
teins involved in internalization could also be phosphorylated
as demonstrated for the MOR. Activation of phospholipase D2
would enhance MOR endocytosis by the activation of p38 kinase
which in turn phosphorylates the Rab5 effector early endosome
antigen 1 required for this process (Yang et al., 2010).
Role of arrestins in OR internalization
The involvement of arrestins in OR internalization was demon-
strated by direct (selective knock-down of arrestin expression)
or indirect approaches (visualization of arrestin translocation to
plasma membrane) (Table 2).
DAMGO-induced MOR internalization in striatal neurons is
impaired by over-expression of a dominant negative mutant of
arrestin 2 corresponding to the last 100 amino acids (arrestin 2
319–418) (Haberstock-Debic et al., 2005). Etorphine also induces
an arrestin-dependent MOR internalization as shown by the
reduction of receptor endocytosis when the dominant negative
mutant V53D of arrestin is over-expressed (Zhang et al., 1998).
While DAMGO triggers MOR internalization by recruiting either
arrestin 2 or 3, morphine selectively interacts with arrestin 3
which is recruited at the plasma membrane to promote MOR
internalization (Groer et al., 2011). In HEK cells, morphine is a
poor inducer of MOR internalization. Whereas over-expression
of arrestin 2 alone has not significant impact, over-expression
of GRK2 greatly enhances receptor sequestration; such GRK2-
mediated MOR internalization is potentiated when both kinase
and arrestin 2 are both co- and over-expressed (Zhang et al.,
1998). The lack of MOR internalization upon activation with
herkinorin would be due to the absence of interaction between
receptor and arrestin 3 (Groer et al., 2007). The constitutive
MOR internalization is also arrestin 3-dependent (Walwyn et al.,
2007). Whereas those reports indicate the crucial role of arrestins
in MOR endocytosis, this was recently challenged by Quillinan
et al. who still observed a MOR internalization upon [Met5]-
enkephalin exposure in arrestin 3 KO mice (Quillinan et al.,
2011). In a recent work, the group of von Zastrow showed that
after being recruited by the phosphorylated MOR, arrestin 3 acts
as a scaffold, promoting ubiquitination of two lysyl residues in
the first intracellular loop by the ubiquitin ligase Smurf2 (Henry
et al., 2012). Epsin 1, through its ubiquitin-interacting motifs,
recognizes the ubiquitinated MOR contained in the clathrin-
coated pits and triggers scission of the vesicle from the cell
surface. Those data revealed new inter-relations between MOR
phosphorylation and ubiquitination with internalization.
Table 2 | Role of arrestins in OR trafficking.
OR Main results References
MOR Inhibition of DAMGO-induced MOR internalization by a dominant negative mutant of arrestin 2 in
striatal neurons
Haberstock-Debic et al.,
2005
Inhibition of etorphine-induced MOR internalization by a dominant negative mutant of arrestin 2 Zhang et al., 1998
Morphine promotes MOR internalization by arrestin 3 while upon DAMGO exposure both arrestins 2
and 3 are recruited
Groer et al., 2011
Morphine induces MOR endocytosis only when GRK2 and arrestin 2 are co-expressed Zhang et al., 1998
Herkinorin is unable to promote MOR sequestration Groer et al., 2007
MOR is still internalized upon [Met5]-enkephalin exposure in arrestin 3 KO mice Quillinan et al., 2011
The arrestin 3 reduces recycling of MOR upon chronic morphine but not methadone exposure Quillinan et al., 2011
Role of arrestin 2 in MOR recycling upon sustained activation by DAMGO but not morphine Groer et al., 2007
DOR DOR endocytosis promoted by DPDPE involves both arrestins 2 and 3. Only arrestin 3 can mediate
sequestration of a non-phosphorylated DOR mutant
Zhang et al., 2005
Arrestin 2 preferentially interacts with DOR to induce its sequestration Qiu et al., 2007
Arrestin 2 is involved in DOR internalization upon etorphine but not DPDPE or deltorphin I exposure Aguila et al., 2012
Arrestin 3 targets DOR to lysosome when activated by SNC-80 but not DPDPE Audet et al., 2012
KOR Inhibition of U50,488-induced KOR internalization by a dominant negative mutant of arrestin 2 Li et al., 1999
Frontiers in Pharmacology | Neuropharmacology December 2014 | Volume 5 | Article 280 | 10
Allouche et al. Opioid receptor desensitization
DPDPE also enables arrestin-mediated endocytosis of DOR as
shown by the partial reduction of internalization when arrestins
2 or 3 are selectively inhibited (Zhang et al., 2005). The triple
DOR mutant T358A/T361A/S363G is still able to internalize
but only when arrestin 3 is expressed. This could explain the
plasma membrane translocation of arrestin 3-GFP observed in
the study of Navratilova and colleagues with the S363A DOR
mutant (Navratilova et al., 2007). DOR endocytosis is severely
impaired in MEFs obtained from single KO mice for arrestin 2
indicating a preferential interaction between those two proteins
(Qiu et al., 2007). It is noteworthy that even when expression of
both arrestins 2 and 3 expression is inhibited, a weak proportion
of DOR is able to internalize. This is in good agreement with data
obtained by Aguila and collaborators who showed that inhibition
of arrestin 2 expression reduces etorphine-induced hDOR endo-
cytosis but not upon DPDPE or deltorphin I exposure (Aguila
et al., 2012).
As demonstrated for MOR and DOR, KOR also undergoes an
arrestin-dependent sequestration when activated by U50,488 as
shown by the reduction of internalization when the dominant
negative mutant arrestin 2 319–418 is over-expressed (Li et al.,
1999).
Together, those data indicate that arrestins are key partners
of OR internalization but under specific conditions or agonist
exposure, other arrestin-independent mechanisms could occur.
Relationship between OR internalization and desensitization
Arttamangkul and collaborators studied desensitization on
potassium currents and internalization in neurons from locus
coeruleus of transgenic mice expressing a FLAG-tagged MOR
(Arttamangkul et al., 2008). Three kinds of ligands can be iden-
tified: those which promote both desensitization and internal-
ization ([Met5]-enkephalin, etorphine, and methadone), those
which induce a desensitization without internalization (mor-
phine and oxymorphone) and oxycodone which promote
neither desensitization nor internalization. This reveals the
absence of any strong association between internalization and
desensitization.
In the Xenopus oocyte expression system, it is possible to
observe an acute desensitization of DOR on potassium channels
(Kir3) elicited by DPDPEwithout significant internalizationmea-
sured by surface biotinylation (Celver et al., 2013). When DOR
internalization is significantly inhibited by over-expression of the
dominant negative mutant of dynamin (K44E), the desensitiza-
tion promoted by sustained exposure to DPDPE is not altered
(Qiu et al., 2007). This is in good agreement with the observa-
tion of Marie et al. who showed that hypertonic sucrose solution
totally blocks hDOR endocytosis without any impact on DPDPE-
and deltorphin I-induced desensitization (Marie et al., 2003b).
Likewise, UFP-512 promotes a strong DOR endocytosis after
15min exposure without significant desensitization on the cAMP
pathway (Aguila et al., 2007). However, upon etorphine exposure
a partial reduction of hDOR desensitization is measured when
internalization is inhibited.
In contrast, the abolition of rKOR internalization by the S369A
substitution also inhibits receptor desensitization on potassium
currents (Mclaughlin et al., 2003).
Those data demonstrate that desensitization and internaliza-
tion are usually two independent processes although in some
situations a close relationship could be evidenced. Those appar-
ent discrepancies may be related to the different behavior of MOR
and DOR in terms of trafficking (see below). For MOR, inter-
nalization would rather promotes recycling and resensitization;
when blocking endocytosis, desensitization would be increased.
In contrast, DOR are preferentially targeted to degradation, and
inhibition of endocytosis would reduce their desensitization;
however, this assumption assumes that the receptor at the plasma
membrane is not uncoupled from G proteins and it’s not always
the case.
OR trafficking
Once internalized, the OR can follow different routes: sequestra-
tion into endosomes, recycling back to the cell surface or targeting
to degradation.
The group of Von Zastrow was the first to identify a protein,
named GASP for GPCR associated sorting protein, which could
actively target DOR to lysosome (Whistler et al., 2002). This pro-
tein selectively interacts with the C terminal region of DOR, not
MOR, that could explain that under certain circumstances, DOR
is degraded while MOR is recycled (Tsao and Von Zastrow, 2000;
Whistler et al., 2002). The same group also identified a motif
localized at the C terminal region of MOR that enables an active
recycling (Tanowitz and Von Zastrow, 2003). This sequence is
lacking in DOR but the chimeric DOR containing the last 17
amino acids of MOR recycles after DADLE activation in con-
trast to wild type. Arrestin 3, dynamin and GRK2 also participate
to MOR resensitization on the activation of potassium channels
in neurons from the locus coeruleus of mice treated during 6
days with morphine (Dang et al., 2011). This could suggest that
those proteins would be involved in MOR trafficking after its
internalization and that internalization itself contributes to resen-
sitization (Dang and Christie, 2012). Using neurons obtained
from the locus coeruleus of transgenic mice expressing a FLAG-
taggedMOR, chronicmorphine but notmethadone during 6 days
was shown to inhibit resensitization and recycling after an acute
[Met5]-enkephalin exposure (Quillinan et al., 2011). Such weak
resensitization and recycling return to the level observed in naive
mice when arrestin 3 was knocked-down indicating that this pro-
tein would also play a pivotal role in MOR trafficking. Arrestin
2 could regulate post-endocytic sorting of MOR upon DAMGO
exposure but not morphine by enabling receptor ubiquitination,
as described for different GPCRs (Marchese and Trejo, 2013),
but also dephosphorylation on the S375 (Groer et al., 2011).
The first hypothesis is unlikely since the sorting of the MOR
either toward recycling or lysosomal degradation does not rely on
receptor ubiquitination (Hislop et al., 2011). The recycling pro-
cess involves protein kinases as shown by staurosporine, which
increases recycling and resensitization after [Met5]-enkephalin
exposure (Arttamangkul et al., 2012). Resensitization of MOR
after [Met5]-enkephalin- or morphine-induced acute desensi-
tization but not cellular tolerance involves dephosphorylation
mediated by protein phosphatases sensitive to calyculin A but not
okadaic acid (Levitt and Williams, 2012). Similarly, Doll and col-
leagues showed that the rapid MOR dephosphorylation at S375
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involves the protein phosphatase 1γ which increases the recy-
cling of receptors contained in endosomes to cell surface (Doll
et al., 2012). The role of receptor dephosphorylation was also
demonstrated for both recycling and resensitization of DOR after
etorphine treatment (Hasbi et al., 2000).
As indicated above, DOR was initially described as a receptor
sorted to lysosomal degradation (Tsao and Von Zastrow, 2000).
However, etorphine, [Leu5]- and [Met5]-enkephalins rather pro-
mote a recycling of hDOR while DPDPE, Deltorphin I or SNC-80
induce a degradation and a down-regulation (Marie et al., 2003b;
Lecoq et al., 2004). This indicates that the differential sorting of
DOR either to recycling or degradation pathway depends on the
agonist used and refers to the notion of biased agonism. Audet
and collaborators found that DOR activated by SNC-80 strongly
interacts with arrestin 3 (Audet et al., 2012). Consequently, the
receptor is mainly targeted to lysosome while upon DPDPE expo-
sure, interactions between DOR and arrestin 3 are loose allowing
receptor recycling. The ability of DOR to recycle also depends
on the duration of agonist exposure. For instance, after 30min
of etorphine treatment, DOR recycles while after 4 h this process
is severely impaired (Hasbi et al., 2000). Zhang and collabo-
rators showed different mechanisms to explain the differential
sorting of DOR (Zhang et al., 2008): when the receptor is phos-
phorylated by GRK2 and internalized via arrestins it can recy-
cle whereas in a non-phosphorylated form DOR undergoes an
arrestin-independent sequestration which is followed by a degra-
dation. As described for MOR, kinases can be involved in OR
sorting. Src was shown to inhibit DOR recycling upon DPDPE
treatment that would favor desensitization on the cAMP pathway
(Archer-Lahlou et al., 2009). Recently, the endothelin converting
enzyme-2, localized in endosomes, was shown to modulate recy-
cling of DOR by degrading opioid peptides such as deltorphin
II or the opioid peptide bovine adrenal medulla 22 (BAM22),
a cleavage product of proenkephalin (Gupta et al., 2014). When
this enzyme is inhibited, DOR recycling decreases and conse-
quently, the desensitization increases. It is noteworthy that this
enzyme is ineffective when DOR is activated by the endoge-
nous peptide [Met5]-enkephalin and has no role on receptor
internalization.
MOLECULAR MECHANISMS INVOLVED IN OR DESENSITIZATION: A
UNIFIED MECHANISM?
The vast majority of studies on OR desensitization demonstrated
that phosphorylation of OR constitutes a rapid and ubiquitous
regulatory mechanisms. However, as illustrated for MOR, quanti-
tative (Lau et al., 2011) or qualitative (Just et al., 2013) differences
in MOR phosphorylation were reported upon DAMGO and
morphine exposure and those differences in multi-site phospho-
rylation would result in differential interactions with partners.
Conversely, some studies using phosphorylation-deficient recep-
tor challenged this paradigm (Qiu et al., 2003). OR phosphory-
lation should rather be viewed as a potentiating mechanism that
would increase binding of regulatory proteins such as arrestins to
the receptor. Mechanisms of desensitization share common fea-
tures (phosphorylation, accessory proteins involvement such as
arrestin, importance of endocytosis and receptor trafficking) and
will dependent not only on agonist (biased agonism) but also on
time exposure, cell system and receptor. All those mechanisms are
depicted in Figures 2A,B.
OPIOID TOLERANCE
DEFINITION
Drug tolerance is the body’s ability to protect itself against the
presence of a drug. It is generally observed after protracted expo-
sure but also after acute treatment (acute tolerance) and it is
not observed for all the pharmacological effects. For opioids,
tolerance to analgesia has been primarily studied as it is the
main issue in clinical practice. In rodent, the ability of opi-
oid to promote analgesia to different type of stimuli could be
measured using numerous behavioral paradigms including hot-
plate test and tail-flick for thermal nociception (Barrot, 2012).
Different parameters could modulate tolerance such as the opi-
oid agonist used (Enquist et al., 2012), duration of treatment
(Soignier et al., 2004), doses (Huidobro et al., 1976) and even
the pharmacological effect observed (Mohammed et al., 2013).
So, it is now established that tolerance to respiratory depres-
sion is lower than the tolerance to analgesia (Mohammed et al.,
2013) and might explain fatal overdoses (White and Irvine,
1999).
OPIOID RECEPTOR-RELATED MECHANISMS OF TOLERANCE
Mechanisms of opioid tolerance are complex and multifaceted.
We will focus on the mechanisms directly related to recep-
tor regulation such as down-regulation, G protein uncoupling,
desensitization, and internalization. Indeed, other mechanisms
contribute to tolerance such as activation of anti-opioid systems
(NPFF, NMDA) (Ueda and Ueda, 2009) but they are beyond the
scope of this review.
Down-regulation
Down-regulation is the reduction of receptor number that may
result from receptor internalization followed by their degrada-
tion, or decrease in receptor synthesis. So, one could hypothesize
that it would contribute to tolerance by diminishing the quan-
tity of available receptor. In vivo, chronic treatment with opioids
promotes decrease (down-regulation), no change or increase (up-
regulation) of OR (Bernstein and Welch, 1998; Stafford et al.,
2001; Fabian et al., 2002). When downregulation is observed,
tolerance might be measured (Gomes et al., 2002) however in
some cases tolerance occurs without receptor downregulation
(Polastron et al., 1994). These data suggest that downregulation
is not mandatory for tolerance.
Desensitization
Desensitization and tolerance are very similar in their defini-
tion as they both include the notion of a reduced response after
prolonged treatment. So, it is tempting to speculate that desen-
sitization and its mechanisms would occur in tolerant animals.
In chronic morphine-treated animals desensitization of OR was
measured on ACase (Noble and Cox, 1996) and associated with
tolerance to analgesic effects (Polastron et al., 1994). In cellular
model, receptor uncoupling from G proteins was demonstrated
to participate in desensitization (see above). Such uncoupling
was also evidenced in vivo after chronic opioid agonist exposure.
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FIGURE 2 | Schematic illustration of mechanisms involved in opioid
receptor desensitization by biased agonists. (A) MOR are differentially
phosphorylated by different kinases upon either DAMGO or morphine
exposure (Doll et al., 2011). This results in binding of arrestins to MOR upon
DAMGO while this interaction is weakly detectable for morphine when a GRK
is over-expressed (Groer et al., 2007). In such conditions, acute DAMGO
exposure promotes G protein uncoupling from MOR while morphine does not
(Whistler and Von Zastrow, 1998). However, MOR phosphorylation at S375
induced by morphine is able to promote desensitization but not internalization
(Schulz et al., 2004). Some reports rather suggest that under morphine
exposure, MOR is not desensitized and this continuous signaling promotes
tolerance (Finn and Whistler, 2001). Even if it’s now well-admitted that
morphine is able to promote MOR internalization (Haberstock-Debic et al.,
2005; Nowoczyn et al., 2013), DAMGO induces a stronger internalization
compared to morphine (Whistler and Von Zastrow, 1998; Schulz et al., 2004).
MOR is dephosphorylated by phosphatase proteins (Doll et al., 2012) then
undergoes an active recycling (Tanowitz and Von Zastrow, 2003). Other
proteins such as arrestins, dynamin, or GRK could participate MOR trafficking
(Dang et al., 2011). In contrast, as morphine is a poor inducer of MOR
internalization, receptor is maintained in a phosphorylation state at S375 for
longer time compared to DAMGO. (B) Different kinases are involved in the
regulation of hDOR (Marie et al., 2008): GRK2 plays a major role in receptor
phosphorylation on S363 upon DPDPE and etorphine while other kinases are
also implicated. Etorphine-induced desensitization requires arrestins but not
receptor internalization. In contrast, an arrestin is involved in hDOR
internalization but not desensitization upon DPDPE (Aguila et al., 2012). Once
sequestrated by etorphine, hDOR is dephosphorylated and recycled back to
the cell surface (Hasbi et al., 2000; Marie et al., 2003b) while upon DPDPE
exposure, the receptor is mainly targeted to lysosomes for degradation (Marie
et al., 2003b) probably by a mechanism involving GASP (Whistler et al., 2002).
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In knock-in mice expressing DOR-eGFP, a challenge with SNC-
80 but not ARM-390 induces a tolerance to analgesic response
in a model of inflammatory pain with a concomitant G pro-
tein uncoupling in both brain and spinal cord homogenates
(Pradhan et al., 2009). Acute and chronic treatment with mor-
phine or fentanyl promotes a similar regulation of MOR. In
parallel with analgesic tolerance, the ability of MOR to enhance
[35S]GTPγS binding was reduced compared to naive animals
(Bohn et al., 2000; Melief et al., 2010). When arrestin 3 was
knocked-out, morphine tolerance and MOR uncoupling from
G proteins was reduced in chronic treated animals (Bohn et al.,
2000). Interestingly, this KO did not affect tolerance induced by
5 days treatment with fentanyl, oxycodone or methadone (Raehal
et al., 2011).
Phosphorylation
Anti-nociceptive tolerance induced by morphine, meperidine,
and fentanyl was shown to be reduced by PKC inhibitors while
DAMGO-induced tolerance andMOR desensitization was shown
to rely on GRK (Hull et al., 2010). Whereas in vitro experiments
showed that S375 is phosphorylated by GRK5 upon morphine
exposure (Doll et al., 2012) and S375 phosphorylation plays a
major role in MOR desensitization (Schulz et al., 2004), S375A
knock-in mice still present anti-nociceptive tolerance upon acute
and chronic exposure to morphine (Grecksch et al., 2011). This
could indicate that MOR desensitization and tolerance are two
unrelated mechanisms. Recently, the role of GRK in morphine
tolerance was also questioned: while morphine predominantly
promotes S375 phosphorylation by GRK5, chronic morphine
treatment induced similar tolerance in wild type and in GRK5
KO mice while dependence was altered (Glück et al., 2014).
Similar results were obtained in GRK3 KO mice, when mor-
phine tolerance to analgesia was unchanged whereas tolerance to
high efficacy agonists, such as fentanyl or U50,488, was reduced
(Terman et al., 2004; Zhang et al., 2013). Rather than inducing
desensitization, a chronic morphine treatment could promote a
compensatory increase in intracellular cAMP level (also named
cAMP overshoot or ACase superactivation) (Avidor-Reiss et al.,
1995) and is believed to play a direct role in tolerance (Duman
et al., 1988; Javed et al., 2004). In this situation, Src kinase can
be recruited at the lipid raft-located MOR and phosphorylates
the Y336 leading to ACase superactivation (Zhang et al., 2009).
While the mechanism is still unclear, it could implicate Ras/Raf-1
which change the MOR, a GPCR, into a receptor tyrosine kinase
like-complex (Zhang et al., 2013).
Endocytosis
Accumulating evidences suggest that OR endocytosis decrease
opioid tolerance but by mechanisms not fully understood. The
first hypothesis has been built byWhistler’s group on the inability
of morphine to promote MOR internalization despite its capac-
ity to induce strong tolerance. In this case, during morphine
treatment, morphine/MOR complexes would accumulate at the
plasma membrane and recruit signaling pathways involved in
tolerance such as ACase superactivation and NMDA receptor reg-
ulation (Finn and Whistler, 2001; He et al., 2002, 2009). In line
with this hypothesis, a knock-in mice, expressing a MOR chimera
where the C-terminus tail was replaced by the C-terminus tail
of DOR, demonstrated less tolerance after chronic morphine
treatment (Kim et al., 2008), correlated to a decrease of toler-
ance biomarkers (He et al., 2009). One explanation of this result
is the termination of signal transduction because the DOR C-
terminus tail will target the chimeric MOR to lysosomes (Finn
and Whistler, 2001). Such results were confirmed when com-
paring other opioid agonist, buprenorphine and etonitazene.
Indeed, buprenorphine, like morphine induces tolerance to anal-
gesia without promoting MOR endocytosis, whereas etonitazene
promotes less tolerance and has the ability to promote MOR
internalization (Grecksch et al., 2006). Interestingly, coadminis-
tration of morphine with subactive doses of internalizing opioids,
DAMGO or methadone, enables morphine-induced internaliza-
tion ofMOR and blocks tolerance development (He andWhistler,
2005). An alternative hypothesis was proposed by Koch and col-
laborators. They proposed that morphine promotes an accumu-
lation of desensitized MOR at the plasma membrane that would
result in an increase in apparent desensitization by inhibiting
resensitization and would promote tolerance (Koch et al., 2001,
2005; Schulz et al., 2004). However, they found that in knock-
in mice expressing MOR mutant S375A substitution, proposed
by these authors to be the primary site of morphine-induced
phosphorylation of MOR responsible for desensitization (Schulz
et al., 2004), morphine tolerance was not affected (Grecksch et al.,
2011). The RAVE (relative activity vs. endocytosis) concept pro-
posed by Whistler et al. (1999) cannot be extended to DOR.
In DOR-eGFP knock-in mice, the internalizing agonist, SNC-
80 promotes acute tolerance to analgesia correlated with strong
internalization whereas ARM-390 a non-internalizing agonist did
not induce acute tolerance (Pradhan et al., 2009, 2010). When
SNC-80 and ARM-390 are chronically administrated, tolerance to
analgesia develops and is dependent on endocytosis with SNC80
but not for ARM-390. Interestingly, no tolerance for locomotor
effects or anxiolysis appears in ARM-390-treated animals under-
lying the fact that biased agonist could be used at the behavioral
level. All those data support the role of internalization andmainly
recycling in reducing tolerance by allowing a sufficient quantity
of functional receptors at the cell surface to produce the biolog-
ical response. However, some opioid agonists such as herkinorin
can promote a long lasting anti-nociception without internaliza-
tion due to the absence of arrestin 3 recruitment (Lamb et al.,
2012).
CONCLUSIONS
All the data presented in this review demonstrated that mecha-
nisms of OR regulation are consistent with themodel proposed by
Lefkowitz (Pierce et al., 2002): agonist activation, receptor phos-
phorylation, arrestin binding, G protein uncoupling, desensitiza-
tion, endocytosis followed by targeting to lysosomes or recycling.
More interestingly, they also showed that many variations around
this model exist depending on the initial conditions, revealing
the complexity of OR regulation now translated to the concept
of biased agonism. It’s an exciting challenge to gain insight this
complexity because it will offer a great opportunity to design new
drugs that will be able to target a particular pharmacological effect
with limited side effects.
Frontiers in Pharmacology | Neuropharmacology December 2014 | Volume 5 | Article 280 | 14
Allouche et al. Opioid receptor desensitization
REFERENCES
Abbadie, C., Pan, Y. X., and Pasternak, G. W. (2004). Immunohistochemical study
of the expression of exon11-containing mu opioid receptor variants in mouse
brain. Neuroscience 127, 419–430. doi: 10.1016/j.neuroscience.2004.03.033
Aguila, B., Coulbault, L., Boulouard, M., Leveille, F., Davis, A., Toth, G., et al.
(2007). In vitro and in vivo pharmacological profile of UFP-512, a novel selec-
tive delta-opioid receptor agonist; correlations between desensitization and
tolerance. Br. J. Pharmacol. 152, 1312–1324. doi: 10.1038/sj.bjp.0707497
Aguila, B., Coulbault, L., Davis, A., Marie, N., Hasbi, A., Le Bras, F., et al. (2012).
ßarrestin1-biased agonism at human delta-opioid receptor by peptidic and
alkaloid ligands. Cell Signal 24, 699–707. doi: 10.1016/j.cellsig.2011.10.018
Allouche, S., Polastron, J., Hasbi, A., Homburger, V., and Jauzac, P. (1999a).
Differential G-protein activation by alkaloid and peptide opioid agonists in the
human neuroblastoma cell line SK-N-BE. Biochem. J. 342 (Pt 1), 71–78. doi:
10.1042/0264-6021:3420071
Allouche, S., Roussel, M., Marie, N., and Jauzac, P. (1999b). Differential desensiti-
zation of human delta-opioid receptors by peptide and alkaloid agonists. Eur. J.
Pharmacol. 371, 235–240. doi: 10.1016/S0014-2999(99)00180-6
Alonso, N., Monczor, F., Echeverria, E., Davio, C., Shayo, C., and Fernandez,
N. (2014). Signal transduction mechanism of biased ligands at histamine H2
receptors. Biochem. J. 459, 117–126. doi: 10.1042/BJ20131226
Anselmi, L., Jaramillo, I., Palacios, M., Huynh, J., and Sternini, C. (2013). Ligand-
induced mu opioid receptor internalization in enteric neurons following
chronic treatment with the opiate fentanyl. J. Neurosci. Res. 91, 854–860. doi:
10.1002/jnr.23214
Appleyard, S. M., Celver, J., Pineda, V., Kovoor, A., Wayman, G. A., and Chavkin,
C. (1999). Agonist-dependent desensitization of the kappa opioid receptor by G
protein receptor kinase and beta-arrestin. J. Biol. Chem. 274, 23802–23807. doi:
10.1074/jbc.274.34.23802
Archer-Lahlou, E., Audet, N., Amraei, M. G., Huard, K., Paquin-Gobeil, M., and
Pineyro, G. (2009). Src promotes delta opioid receptor (DOR) desensitiza-
tion by interfering with receptor recycling. J. Cell. Mol. Med. 13, 147–163. doi:
10.1111/j.1582-4934.2008.00308.x
Arttamangkul, S., Birdsong, W., and Williams, J. T. (2014). Does PKC activation
increase the homologous desensitization of μopioid receptors? Br. J. Pharmacol.
doi: 10.1111/bph.12712
Arttamangkul, S., Lau, E. K., Lu, H.-W., and Williams, J. T. (2012). Desensitization
and trafficking of μ-opioid receptors in locus ceruleus neurons: modulation by
kinases. Mol. Pharmacol. 81, 348–355. doi: 10.1124/mol.111.076208
Arttamangkul, S., Quillinan, N., Low, M. J., Von Zastrow, M., Pintar,
J., and Williams, J. T. (2008). Differential activation and trafficking of
micro-opioid receptors in brain slices. Mol. Pharmacol. 74, 972–979. doi:
10.1124/mol.108.048512
Audet, N., Charfi, I., Mnie-Filali, O., Amraei, M., Chabot-Dore, A. J., Millecamps,
M., et al. (2012). Differential association of receptor-Gbetagamma com-
plexes with beta-arrestin2 determines recycling bias and potential for tol-
erance of delta opioid receptor agonists. J. Neurosci. 32, 4827–4840. doi:
10.1523/JNEUROSCI.3734-11.2012
Avidor-Reiss, T., Bayewitch, M., Levy, R., Matus-Leibovitch, N., Nevo, I., and Vogel,
Z. (1995). Adenylylcyclase supersensitization in mu-opioid receptor-transfected
Chinese hamster ovary cells following chronic opioid treatment. J. Biol. Chem.
270, 29732–29738. doi: 10.1074/jbc.270.50.29732
Bailey, C. P., Oldfield, S., Llorente, J., Caunt, C. J., Teschemacher, A. G., Roberts,
L., et al. (2009). Involvement of PKC alpha and G-protein-coupled receptor
kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature
brain neurons. Br. J. Pharmacol. 158, 157–164. doi: 10.1111/j.1476-5381.2009.
00140.x
Barrot, M. (2012). Tests and models of nociception and pain in rodents.
Neuroscience 211, 39–50. doi: 10.1016/j.neuroscience.2011.12.041
Beckett, A. H., and Casy, A. F. (1954). Stereochemistry of certain analgesics. Nature
173, 1231–1232. doi: 10.1038/1731231a0
Befort, K., Filliol, D., Decaillot, F. M., Gaveriaux-Ruff, C., Hoehe, M. R., and
Kieffer, B. L. (2001). A single nucleotide polymorphic mutation in the human
mu-opioid receptor severely impairs receptor signaling. J. Biol. Chem. 276,
3130–3137. doi: 10.1074/jbc.M006352200
Bernstein,M. A., andWelch, S. P. (1998). mu-Opioid receptor down-regulation and
cAMP-dependent protein kinase phosphorylation in a mouse model of chronic
morphine tolerance. Brain Res. Mol. Brain Res. 55, 237–242. doi: 10.1016/S0169-
328X(98)00005-9
Besse, D., Lombard, M. C., Zajac, J. M., Roques, B. P., and Besson, J. M. (1990).
Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in
the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res
521, 15–22. doi: 10.1016/0006-8993(90)91519-M
Bian, J. M., Wu, N., Su, R. B., and Li, J. (2012). Opioid receptor trafficking and
signaling: what happens after opioid receptor activation? Cell. Mol. Neurobiol.
32, 167–184. doi: 10.1007/s10571-011-9755-5
Blake, A. D., Bot, G., Freeman, J. C., and Reisine, T. (1997a). Differential opioid
agonist regulation of themousemu opioid receptor. J. Biol. Chem. 272, 782–790.
doi: 10.1074/jbc.272.2.782
Blake, A. D., Bot, G., Li, S., Freeman, J. C., and Reisine, T. (1997b). Differential
agonist regulation of the human kappa-opioid receptor. J. Neurochem. 68,
1846–1852. doi: 10.1046/j.1471-4159.1997.68051846.x
Blanchet, C., Sollini, M., and Luscher, C. (2003). Two distinct forms of desensi-
tization of G-protein coupled inwardly rectifying potassium currents evoked
by alkaloid and peptide mu-opioid receptor agonists. Mol. Cell. Neurosci. 24,
517–523. doi: 10.1016/S1044-7431(03)00173-8
Bodnar, R. J. (2014). Endogenous opiates and behavior: 2013. Peptides 62C, 67–136.
doi: 10.1016/j.peptides.2014.09.013
Bohn, L.M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J., and Caron,M. G. (2000).
Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine
tolerance but not dependence. Nature 408, 720–723. doi: 10.1038/35047086
Borgland, S. L., Connor, M., Osborne, P. B., Furness, J. B., and Christie, M. J.
(2003). Opioid agonists have different efficacy profiles for G protein activation,
rapid desensitization, and endocytosis of mu-opioid receptors. J. Biol. Chem.
278, 18776–18784. doi: 10.1074/jbc.M300525200
Bot, G., Blake, A. D., Li, S., and Reisine, T. (1997). Opioid regulation of the mouse
delta-opioid receptor expressed in human embryonic kidney 293 cells. Mol.
Pharmacol. 52, 272–281.
Bradbury, F. A., Zelnik, J. C., and Traynor, J. R. (2009). G protein independent
phosphorylation and internalization of the delta-opioid receptor. J. Neurochem.
109, 1526–1535. doi: 10.1111/j.1471-4159.2009.06082.x
Celver, J., Sharma, M., Thanawala, V., Christopher Octeau, J., and Kovoor,
A. (2013). Arrestin-dependent but G-protein coupled receptor kinase-
independent uncoupling of D2-dopamine receptors. J. Neurochem. 127, 57–65.
doi: 10.1111/jnc.12359
Celver, J., Xu, M., Jin, W., Lowe, J., and Chavkin, C. (2004). Distinct domains of the
mu-opioid receptor control uncoupling and internalization. Mol. Pharmacol.
65, 528–537. doi: 10.1124/mol.65.3.528
Chen, C., Shahabi, V., Xu, W., and Liu-Chen, L. Y. (1998). Palmitoylation of
the rat mu opioid receptor. FEBS Lett. 441, 148–152. doi: 10.1016/S0014-
5793(98)01547-6
Chen, Y. J., Oldfield, S., Butcher, A. J., Tobin, A. B., Saxena, K., Gurevich, V. V., et al.
(2013). Identification of phosphorylation sites in the COOH-terminal tail of the
mu-opioid receptor. J. Neurochem. 124, 189–199. doi: 10.1111/jnc.12071
Chen, Y., Mestek, A., Liu, J., Hurley, J. A., and Yu, L. (1993a). Molecular cloning and
functional expression of a mu-opioid receptor from rat brain. Mol. Pharmacol.
44, 8–12.
Chen, Y., Mestek, A., Liu, J., and Yu, L. (1993b). Molecular cloning of a rat
kappa opioid receptor reveals sequence similarities to the mu and delta opioid
receptors. Biochem. J. 295 (Pt 3), 625–628.
Cheng, Z. J., Yu, Q. M., Wu, Y. L., Ma, L., and Pei, G. (1998). Selective interference
of beta-arrestin 1 with kappa and delta but not mu opioid receptor/G protein
coupling. J. Biol. Chem. 273, 24328–24333. doi: 10.1074/jbc.273.38.24328
Chu, J., Zheng, H., Zhang, Y., Loh, H. H., and Law, P. Y. (2010). Agonist-dependent
mu-opioid receptor signaling can lead to heterologous desensitization. Cell.
Signal. 22, 684–696. doi: 10.1016/j.cellsig.2009.12.003
Clayton, C. C., Bruchas, M. R., Lee,M. L., and Chavkin, C. (2010). Phosphorylation
of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif
reduces agonist efficacy. Mol. Pharmacol. 77, 339–347. doi: 10.1124/mol.109.
060558
Connor, M., Osborne, P. B., and Christie, M. J. (2004). Mu-opioid receptor
desensitization: is morphine different? Br. J. Pharmacol. 143, 685–696. doi:
10.1038/sj.bjp.0705938
Cox, B. M., Goldstein, A., and Hi, C. H. (1976). Opioid activity of a peptide, beta-
lipotropin-(61-91), derived from beta-lipotropin. Proc. Natl. Acad. Sci. U.S.A.
73, 1821–1823. doi: 10.1073/pnas.73.6.1821
Dang, V. C., Chieng, B., Azriel, Y., and Christie, M. J. (2011). Cellular
morphine tolerance produced by betaarrestin-2-dependent impairment
www.frontiersin.org December 2014 | Volume 5 | Article 280 | 15
Allouche et al. Opioid receptor desensitization
of mu-opioid receptor resensitization. J. Neurosci. 31, 7122–7130. doi:
10.1523/JNEUROSCI.5999-10.2011
Dang, V. C., and Christie, M. J. (2012). Mechanisms of rapid opioid receptor desen-
sitization, resensitization and tolerance in brain neurons. Br. J. Pharmacol. 165,
1704–1716. doi: 10.1111/j.1476-5381.2011.01482.x
Dang, V. C., Napier, I. A., and Christie, M. J. (2009). Two distinct mechanisms
mediate acute mu-opioid receptor desensitization in native neurons. J. Neurosci.
29, 3322–3327. doi: 10.1523/JNEUROSCI.4749-08.2009
Dhawan, B. N., Cesselin, F., Raghubir, R., Reisine, T., Bradley, P. B., Portoghese,
P. S., et al. (1996). International Union of Pharmacology. XII. Classification of
opioid receptors. Pharmacol. Rev. 48, 567–592.
Doll, C., Konietzko, J., Poll, F., Koch, T., Hollt, V., and Schulz, S. (2011).
Agonist-selective patterns of micro-opioid receptor phosphorylation revealed
by phosphosite-specific antibodies. Br. J. Pharmacol. 164, 298–307. doi:
10.1111/j.1476-5381.2011.01382.x
Doll, C., Poll, F., Peuker, K., Loktev, A., Gluck, L., and Schulz, S. (2012).
Deciphering micro-opioid receptor phosphorylation and dephosphorylation
in HEK293 cells. Br. J. Pharmacol. 167, 1259–1270. doi: 10.1111/j.1476-
5381.2012.02080.x
Duman, R. S., Tallman, J. F., and Nestler, E. J. (1988). Acute and chronic opiate-
regulation of adenylate cyclase in brain: specific effects in locus coeruleus.
J. Pharmacol. Exp. Ther. 246, 1033–1039.
Ehrlich, G. K., Andria, M. L., Zheng, X., Kieffer, B., Gioannini, T. L., Hiller, J. M.,
et al. (1998). Functional significance of cysteine residues in the delta opioid
receptor studied by site-directed mutagenesis. Can. J. Physiol. Pharmacol. 76,
269–277.
El Kouhen, R., Burd, A. L., Erickson-Herbrandson, L. J., Chang, C. Y., Law, P.
Y., and Loh, H. H. (2001). Phosphorylation of Ser363, Thr370, and Ser375
residues within the carboxyl tail differentially regulates mu-opioid recep-
tor internalization. J. Biol. Chem. 276, 12774–12780. doi: 10.1074/jbc.M009
571200
Enquist, J., Ferwerda, M., Milan-Lobo, L., and Whistler, J. L. (2012). Chronic
methadone treatment shows a better cost/benefit ratio than chronic mor-
phine in mice. J. Pharmacol. Exp. Ther. 340, 386–392. doi: 10.1124/jpet.111.
187583
Evans, C. J., Keith, D. E. Jr., Morrison, H., Magendzo, K., and Edwards, R. H.
(1992). Cloning of a delta opioid receptor by functional expression. Science 258,
1952–1955. doi: 10.1126/science.1335167
Fabian, G., Bozo, B., Szikszay, M., Horvath, G., Coscia, C. J., and Szucs, M. (2002).
Chronic morphine-induced changes in mu-opioid receptors and G proteins of
different subcellular loci in rat brain. J. Pharmacol. Exp. Ther. 302, 774–780. doi:
10.1124/jpet.102.036152
Feng, B., Li, Z., andWang, J. B. (2011). Protein kinase C-mediated phosphorylation
of the mu-opioid receptor and its effects on receptor signaling.Mol. Pharmacol.
79, 768–775. doi: 10.1124/mol.110.069096
Filizola, M., and Devi, L. A. (2013). Grand opening of structure-guided design for
novel opioids. Trends Pharmacol. Sci. 34, 6–12. doi: 10.1016/j.tips.2012.10.002
Finn, A. K., and Whistler, J. L. (2001). Endocytosis of the mu opioid receptor
reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 32,
829–839. doi: 10.1016/S0896-6273(01)00517-7
Fujita, W., Gomes, I., and Devi, L. A. (2014). Heteromers of μ-delta opioid recep-
tors: new pharmacology and novel therapeutic possibilities. Br. J. Pharmacol.
doi: 10.1111/bph.12663. [Epub ahead of print].
Fukuda, K., Kato, S., Mori, K., Nishi, M., Takeshima, H., Iwabe, N., et al. (1994).
cDNA cloning and regional distribution of a novel member of the opioid
receptor family. FEBS Lett. 343, 42–46. doi: 10.1016/0014-5793(94)80603-9
Gahwiler, B. H. (1981). Development of acute tolerance during exposure of
hippocampal explants to an opioid peptide. Brain Res. 217, 196–200. doi:
10.1016/0006-8993(81)90200-6
Gaveriaux-Ruff, C., and Kieffer, B. L. (2002). Opioid receptor genes inactivated in
mice: the highlights. Neuropeptides 36, 62–71. doi: 10.1054/npep.2002.0900
Georgoussi, Z., Merkouris, M., Mullaney, I., Megaritis, G., Carr, C., Zioudrou,
C., et al. (1997). Selective interactions of mu-opioid receptors with pertus-
sis toxin-sensitive G proteins: involvement of the third intracellular loop and
the c-terminal tail in coupling. Biochim. Biophys. Acta 1359, 263–274. doi:
10.1016/S0167-4889(97)00097-9
Gioannini, T. L., Onoprishvili, I., Hiller, J. M., and Simon, E. J. (1999). Inactivation
of the purified bovine mu opioid receptor by sulfhydryl reagents. Neurochem.
Res. 24, 37–42. doi: 10.1023/A:1020923928936
Glück, L., Loktev, A., Moulédous, L., Mollereau, C., Law, P.-Y., and Schulz,
S. (2014). Loss of morphine reward and dependence in mice lacking
G Protein-coupled receptor kinase 5. Biol. Psychiatry. 76, 767–774. doi:
10.1016/j.biopsych.2014.01.021
Goldstein, A., Fischli, W., Lowney, L. I., Hunkapiller, M., and Hood, L. (1981).
Porcine pituitary dynorphin: complete amino acid sequence of the biologi-
cally active heptadecapeptide. Proc. Natl. Acad. Sci. U.S.A. 78, 7219–7223. doi:
10.1073/pnas.78.11.7219
Gomes, B. A., Shen, J., Stafford, K., Patel, M., and Yoburn, B. C. (2002). Mu-opioid
receptor down-regulation and tolerance are not equally dependent upon G-
protein signaling. Pharmacol. Biochem. Behav. 72, 273–278. doi: 10.1016/S0091-
3057(01)00757-2
Granier, S., Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Weis, W. I., et al.
(2012). Structure of the delta-opioid receptor bound to naltrindole.Nature 485,
400–404. doi: 10.1038/nature11111
Grecksch, G., Bartzsch, K., Widera, A., Becker, A., Hollt, V., and Koch, T. (2006).
Development of tolerance and sensitization to different opioid agonists in rats.
Psychopharmacology (Berl) 186, 177–184. doi: 10.1007/s00213-006-0365-8
Grecksch, G., Just, S., Pierstorff, C., Imhof, A. K., Gluck, L., Doll, C., et al. (2011).
Analgesic tolerance to high-efficacy agonists but not to morphine is dimin-
ished in phosphorylation-deficient S375A mu-opioid receptor knock-in mice.
J. Neurosci. 31, 13890–13896. doi: 10.1523/JNEUROSCI.2304-11.2011
Groer, C. E., Schmid, C. L., Jaeger, A. M., and Bohn, L. M. (2011). Agonist-directed
interactions with specific beta-arrestins determine mu-opioid receptor traffick-
ing, ubiquitination, and dephosphorylation. J. Biol. Chem. 286, 31731–31741.
doi: 10.1074/jbc.M111.248310
Groer, C. E., Tidgewell, K., Moyer, R. A., Harding, W. W., Rothman, R. B.,
Prisinzano, T. E., et al. (2007). An opioid agonist that does not induce
mu-opioid receptor–arrestin interactions or receptor internalization. Mol.
Pharmacol. 71, 549–557. doi: 10.1124/mol.106.028258
Guillemin, R., Vargo, T., Rossier, J., Minick, S., Ling, N., Rivier, C., et al. (1977).
Beta-Endorphin and adrenocorticotropin are selected concomitantly by the
pituitary gland. Science 197, 1367–1369. doi: 10.1126/science.197601
Guo, J., Wu, Y., Zhang, W., Zhao, J., Devi, L. A., Pei, G., et al. (2000). Identification
of G protein-coupled receptor kinase 2 phosphorylation sites responsible for
agonist-stimulated delta-opioid receptor phosphorylation. Mol. Pharmacol. 58,
1050–1056. doi: 10.1124/mol.58.5.1050
Gupta, A., Fujita, W., Gomes, I., Bobeck, E., and Devi, L. A. (2014). Endothelin
converting enzyme-2 differentially regulates opioid receptor activity. Br. J.
Pharmacol. doi: 10.1111/bph.12833. [Epub ahead of print].
Haberstock-Debic, H., Kim, K.-A., Yu, Y. J., and Von Zastrow, M. (2005). Morphine
promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in
striatal neurons. J. Neurosci. 25, 7847–7857. doi: 10.1523/JNEUROSCI.5045-
04.2005
Haberstock-Debic, H., Wein, M., Barrot, M., Colago, E. E., Rahman, Z., Neve, R. L.,
et al. (2003). Morphine acutely regulates opioid receptor trafficking selectively
in dendrites of nucleus accumbens neurons. J. Neurosci. 23, 4324–4332.
Hasbi, A., Allouche, S., Sichel, F., Stanasila, L., Massotte, D., Landemore, G., et al.
(2000). Internalization and recycling of delta-opioid receptor are dependent
on a phosphorylation-dephosphorylation mechanism. J. Pharmacol. Exp. Ther.
293, 237–247.
He, L., Fong, J., Von Zastrow, M., and Whistler, J. L. (2002). Regulation of opioid
receptor trafficking and morphine tolerance by receptor oligomerization. Cell
108, 271–282. doi: 10.1016/S0092-8674(02)00613-X
He, L., Kim, J. A., and Whistler, J. L. (2009). Biomarkers of morphine tolerance
and dependence are prevented by morphine-induced endocytosis of a mutant
mu-opioid receptor. FASEB J. 23, 4327–4334. doi: 10.1096/fj.09-133223
He, L., and Whistler, J. L. (2005). An opiate cocktail that reduces morphine tol-
erance and dependence. Curr. Biol. 15, 1028–1033. doi: 10.1016/j.cub.2005.
04.052
Henry, A. G., Hislop, J. N., Grove, J., Thorn, K., Marsh, M., and Von Zastrow, M.
(2012). Regulation of endocytic clathrin dynamics by cargo ubiquitination.Dev.
Cell 23, 519–532. doi: 10.1016/j.devcel.2012.08.003
Hislop, J. N., Henry, A. G., and Von Zastrow, M. (2011). Ubiquitination in
the first cytoplasmic loop of μ-opioid receptors reveals a hierarchical mech-
anism of lysosomal down-regulation. J. Biol. Chem. 286, 40193–40204. doi:
10.1074/jbc.M111.288555
Hong, M. H., Xu, C., Wang, Y. J., Ji, J. L., Tao, Y. M., Xu, X. J.,
et al. (2009). Role of Src in ligand-specific regulation of delta-opioid
Frontiers in Pharmacology | Neuropharmacology December 2014 | Volume 5 | Article 280 | 16
Allouche et al. Opioid receptor desensitization
receptor desensitization and internalization. J. Neurochem. 108, 102–114. doi:
10.1111/j.1471-4159.2008.05740.x
Hughes, J., Smith, T. W., Kosterlitz, H. W., Fothergill, L. A., Morgan, B. A., and
Morris, H. R. (1975). Identification of two related pentapeptides from the
brain with potent opiate agonist activity. Nature 258, 577–580. doi: 10.1038/
258577a0
Huidobro, F., Huidobro-Toro, J. P., and Leong Way, E. (1976). Studies on tolerance
development to single doses of morphine in mice. J. Pharmacol. Exp. Ther. 198,
318–329.
Hull, L. C., Llorente, J., Gabra, B. H., Smith, F. L., Kelly, E., Bailey, C., et al. (2010).
The effect of protein kinase C and G protein-coupled receptor kinase inhibition
on tolerance induced by mu-opioid agonists of different efficacy. J. Pharmacol.
Exp. Ther. 332, 1127–1135. doi: 10.1124/jpet.109.161455
Illing, S., Mann, A., and Schulz, S. (2014). Heterologous regulation of agonist-
independent mu-opioid receptor phosphorylation by protein kinase C. Br. J.
Pharmacol. 171, 1330–1340. doi: 10.1111/bph.12546
Javed, R. R., Dewey, W. L., Smith, P. A., and Smith, F. L. (2004). PKC
and PKA inhibitors reverse tolerance to morphine-induced hypothermia
and supraspinal analgesia in mice. Eur. J. Pharmacol. 492, 149–157. doi:
10.1016/j.ejphar.2004.03.061
Johnson, E. A., Oldfield, S., Braksator, E., Gonzalez-Cuello, A., Couch, D., Hall, K.
J., et al. (2006). Agonist-selective mechanisms of mu-opioid receptor desensiti-
zation in human embryonic kidney 293 cells.Mol. Pharmacol. 70, 676–685. doi:
10.1124/mol.106.022376
Just, S., Illing, S., Trester-Zedlitz, M., Lau, E. K., Kotowski, S. J., Miess, E.,
et al. (2013). Differentiation of opioid drug effects by hierarchical multi-site
phosphorylation. Mol. Pharmacol. 83, 633–639. doi: 10.1124/mol.112.082875
Kakidani, H., Furutani, Y., Takahashi, H., Noda, M., Morimoto, Y., Hirose, T.,
et al. (1982). Cloning and sequence analysis of cDNA for porcine beta-
neo-endorphin/dynorphin precursor. Nature 298, 245–249. doi: 10.1038/
298245a0
Keith, D. E., Anton, B., Murray, S. R., Zaki, P. A., Chu, P. C., Lissin, D. V.,
et al. (1998). mu-Opioid receptor internalization: opiate drugs have differen-
tial effects on a conserved endocytic mechanism in vitro and in the mammalian
brain. Mol. Pharmacol. 53, 377–384.
Kelly, E. (2013). Ligand bias at the mu-opioid receptor. Biochem. Soc. Trans. 41,
218–224. doi: 10.1042/BST20120331
Kenakin, T. (2011). Functional selectivity and biased receptor signaling.
J. Pharmacol. Exp. Ther. 336, 296–302. doi: 10.1124/jpet.110.173948
Kieffer, B. L. (1999). Opioids: first lessons from knockout mice. Trends Pharmacol.
Sci. 20, 19–26. doi: 10.1016/S0165-6147(98)01279-6
Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C., and Hirth, C. G. (1992). The delta-
opioid receptor: isolation of a cDNA by expression cloning and pharmaco-
logical characterization. Proc. Natl. Acad. Sci. U.S.A. 89, 12048–12052. doi:
10.1073/pnas.89.24.12048
Kim, J. A., Bartlett, S., He, L., Nielsen, C. K., Chang, A. M., Kharazia, V.,
et al. (2008). Morphine-induced receptor endocytosis in a novel knockin
mouse reduces tolerance and dependence. Curr. Biol. 18, 129–135. doi:
10.1016/j.cub.2007.12.057
Knapp, R. J., Malatynska, E., Collins, N., Fang, L., Wang, J. Y., Hruby, V. J., et al.
(1995). Molecular biology and pharmacology of cloned opioid receptors. FASEB
J. 9, 516–525.
Koch, T., Schulz, S., Pfeiffer, M., Klutzny, M., Schroder, H., Kahl, E., et al.
(2001). C-terminal splice variants of the mouse mu-opioid receptor differ in
morphine-induced internalization and receptor resensitization. J. Biol. Chem.
276, 31408–31414. doi: 10.1074/jbc.M100305200
Koch, T., Widera, A., Bartzsch, K., Schulz, S., Brandenburg, L. O., Wundrack,
N., et al. (2005). Receptor endocytosis counteracts the development of opioid
tolerance. Mol. Pharmacol. 67, 280–287. doi: 10.1124/mol.104.004994
Konig, C., Gavrilova-Ruch, O., Von Banchet, G. S., Bauer, R., Grun, M., Hirsch,
E., et al. (2010). Modulation of mu opioid receptor desensitization in periph-
eral sensory neurons by phosphoinositide 3-kinase gamma. Neuroscience 169,
449–454. doi: 10.1016/j.neuroscience.2010.04.068
Kouhen, O. M., Wang, G., Solberg, J., Erickson, L. J., Law, P. Y., and Loh, H.
H. (2000). Hierarchical phosphorylation of delta-opioid receptor regulates
agonist-induced receptor desensitization and internalization. J. Biol. Chem. 275,
36659–36664. doi: 10.1074/jbc.M006788200
Kovoor, A., Celver, J., Abdryashitov, R. I., Chavkin, C., and Gurevich, V. V.
(1999). Targeted construction of phosphorylation-independent beta-arrestin
mutants with constitutive activity in cells. J. Biol. Chem. 274, 6831–6834. doi:
10.1074/jbc.274.11.6831
Kramer, H. K., Andria, M. L., Esposito, D. H., and Simon, E. J. (2000a). Tyrosine
phosphorylation of the delta-opioid receptor. Evidence for its role in mitogen-
activated protein kinase activation and receptor internalization*. Biochem.
Pharmacol. 60, 781–792. doi: 10.1016/S0006-2952(00)00400-7
Kramer, H. K., Andria, M. L., Kushner, S. A., Esposito, D. H., Hiller, J. M.,
and Simon, E. J. (2000b). Mutation of tyrosine 318 (Y318F) in the delta-
opioid receptor attenuates tyrosine phosphorylation, agonist-dependent recep-
tor internalization, and mitogen-activated protein kinase activation. Brain Res.
Mol. Brain Res. 79, 55–66. doi: 10.1016/S0169-328X(00)00097-8
Lamb, K., Tidgewell, K., Simpson, D. S., Bohn, L. M., and Prisinzano, T. E. (2012).
Antinociceptive effects of herkinorin, a MOP receptor agonist derived from
salvinorin A in the formalin test in rats: new concepts in mu opioid receptor
pharmacology: from a symposium on new concepts in mu-opioid pharma-
cology. Drug Alcohol Depend. 121, 181–188. doi: 10.1016/j.drugalcdep.2011.
10.026
Lau, E. K., Trester-Zedlitz, M., Trinidad, J. C., Kotowski, S. J., Krutchinsky, A. N.,
Burlingame, A. L., et al. (2011). Quantitative encoding of the effect of a par-
tial agonist on individual opioid receptors by multisite phosphorylation and
threshold detection. Sci. Signal. 4, ra52. doi: 10.1126/scisignal.2001748
Law, P. Y., Hom, D. S., and Loh, H. H. (1982). Loss of opiate receptor activity in
neuroblastoma X glioma NG108-15 hybrid cells after chronic opiate treatment.
A multiple-step process. Mol. Pharmacol. 22, 1–4.
Law, P. Y., Wong, Y. H., and Loh, H. H. (2000). Molecular mechanisms and regu-
lation of opioid receptor signaling. Annu. Rev. Pharmacol. Toxicol. 40, 389–430.
doi: 10.1146/annurev.pharmtox.40.1.389
Lecoq, I., Marie, N., Jauzac, P., and Allouche, S. (2004). Different regulation of
human delta-opioid receptors by SNC-80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-
allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenz yl]-N,N-diethylbenzamide]
and endogenous enkephalins. J. Pharmacol. Exp. Ther. 310, 666–677. doi:
10.1124/jpet.103.063958
Levitt, E. S., and Williams, J. T. (2012). Morphine desensitization and cellular tol-
erance are distinguished in rat locus ceruleus neurons. Mol. Pharmacol. 82,
983–992. doi: 10.1124/mol.112.081547
Li, J. G., Luo, L. Y., Krupnick, J. G., Benovic, J. L., and Liu-Chen, L. Y. (1999).
U50,488H-induced internalization of the human kappa opioid receptor involves
a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internal-
ization is not required for mitogen-activated protein kinase activation. J. Biol.
Chem. 274, 12087–12094. doi: 10.1074/jbc.274.17.12087
Li, J. G., Zhang, F., Jin, X. L., and Liu-Chen, L. Y. (2003). Differential regu-
lation of the human kappa opioid receptor by agonists: etorphine and lev-
orphanol reduced dynorphin A- and U50,488H-induced internalization and
phosphorylation. J. Pharmacol. Exp. Ther. 305, 531–540. doi: 10.1124/jpet.102.
045559
Li, J., Li, J.-G., Chen, C., Zhang, F., and Liu-Chen, L.-Y. (2002). Molecular
basis of differences in (-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)-
cyclohexyl]benzeneacetamide-induced desensitization and phosphorylation
between human and rat kappa-opioid receptors expressed in Chinese hamster
ovary cells. Mol. Pharmacol. 61, 73–84. doi: 10.1124/mol.61.1.73
Ling, K., Ma, L., and Pei, G. (1998). Differential efficacies of kappa agonists to
induce homologous desensitization of human kappa opioid receptor. Neurosci.
Lett. 240, 25–28. doi: 10.1016/S0304-3940(97)00921-X
Liu, J. G., Liao, X. P., Gong, Z. H., and Qin, B. Y. (1999a). The difference between
methadone and morphine in regulation of delta-opioid receptors underlies the
antagonistic effect of methadone on morphine-mediated cellular actions. Eur. J.
Pharmacol. 373, 233–239. doi: 10.1016/S0014-2999(99)00270-8
Liu, J. G., Liao, X. P., Gong, Z. H., and Qin, B. Y. (1999b). Methadone-induced
desensitization of the delta-opioid receptor is mediated by uncoupling of
receptor from G protein. Eur. J. Pharmacol. 374, 301–308. doi: 10.1016/S0014-
2999(99)00322-2
Liu, J. G., and Prather, P. L. (2001). Chronic exposure to mu-opioid agonists pro-
duces constitutive activation of mu-opioid receptors in direct proportion to the
efficacy of the agonist used for pretreatment. Mol. Pharmacol. 60, 53–62.
Llorente, J., Lowe, J. D., Sanderson, H. S., Tsisanova, E., Kelly, E., Henderson, G.,
et al. (2012). mu-Opioid receptor desensitization: homologous or heterologous?
Eur. J. Neurosci. 36, 3636–3642. doi: 10.1111/ejn.12003
Lowe, J. D., Celver, J. P., Gurevich, V. V., and Chavkin, C. (2002). mu-
Opioid receptors desensitize less rapidly than delta-opioid receptors due to
www.frontiersin.org December 2014 | Volume 5 | Article 280 | 17
Allouche et al. Opioid receptor desensitization
less efficient activation of arrestin. J. Biol. Chem. 277, 15729–15735. doi:
10.1074/jbc.M200612200
Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara,
R. K., et al. (2012). Crystal structure of the micro-opioid receptor bound to a
morphinan antagonist. Nature 485, 321–326. doi: 10.1038/nature10954
Mann, A., Illing, S., Miess, E., and Schulz, S. (2014). Different mechanisms
of homologous and heterologous μ-opioid receptor phosphorylation. Br. J.
Pharmacol. doi: 10.1111/bph.12627. [Epub ahead of print].
Mansour, A., Fox, C. A., Akil, H., and Watson, S. J. (1995). Opioid-receptor mRNA
expression in the rat CNS: anatomical and functional implications. Trends
Neurosci. 18, 22–29. doi: 10.1016/0166-2236(95)93946-U
Marchese, A., and Trejo, J. (2013). Ubiquitin-dependent regulation of G protein-
coupled receptor trafficking and signaling. Cell. Signal. 25, 707–716. doi:
10.1016/j.cellsig.2012.11.024
Marie, N., Aguila, B., Hasbi, A., Davis, A., Jauzac, P., and Allouche, S. (2008).
Different kinases desensitize the human delta-opioid receptor (hDOP-R) in
the neuroblastoma cell line SK-N-BE upon peptidic and alkaloid agonists. Cell.
Signal. 20, 1209–1220. doi: 10.1016/j.cellsig.2008.02.010
Marie, N., Landemore, G., Debout, C., Jauzac, P., and Allouche, S. (2003a).
Pharmacological characterization of AR-M1000390 at human delta opioid
receptors. Life Sci. 73, 1691–1704. doi: 10.1016/S0024-3205(03)00489-2
Marie, N., Lecoq, I., Jauzac, P., and Allouche, S. (2003b). Differential sorting
of human delta-opioid receptors after internalization by peptide and alkaloid
agonists. J. Biol. Chem. 278, 22795–22804. doi: 10.1074/jbc.M300084200
Massotte, D. (2014). In vivo opioid receptor heteromerization: where do we stand?
Br. J. Pharmacol. doi: 10.1111/bph.12702. [Epub ahead of print].
Mclaughlin, J. P., Myers, L. C., Zarek, P. E., Caron, M. G., Lefkowitz, R. J., Czyzyk, T.
A., et al. (2004). Prolonged kappa opioid receptor phosphorylation mediated by
G-protein receptor kinase underlies sustained analgesic tolerance. J. Biol. Chem.
279, 1810–1818. doi: 10.1074/jbc.M305796200
Mclaughlin, J. P., Xu, M., Mackie, K., and Chavkin, C. (2003). Phosphorylation
of a carboxyl-terminal serine within the kappa-opioid receptor produces
desensitization and internalization. J. Biol. Chem. 278, 34631–34640. doi:
10.1074/jbc.M304022200
Mcpherson, J., Rivero, G., Baptist, M., Llorente, J., Al-Sabah, S., Krasel, C.,
et al. (2010). μ-opioid receptors: correlation of agonist efficacy for signalling
with ability to activate internalization. Mol. Pharmacol. 78, 756–766. doi:
10.1124/mol.110.066613
Megaritis, G., Merkouris, M., and Georgoussi, Z. (2000). Functional domains
of delta- and mu-opioid receptors responsible for adenylyl cyclase inhibition.
Receptors Channels 7, 199–212.
Melief, E. J., Miyatake, M., Bruchas, M. R., and Chavkin, C. (2010). Ligand-directed
c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc.
Natl. Acad. Sci. U.S.A. 107, 11608–11613. doi: 10.1073/pnas.1000751107
Meng, F., Xie, G. X., Thompson, R. C., Mansour, A., Goldstein, A., Watson,
S. J., et al. (1993). Cloning and pharmacological characterization of a rat
kappa opioid receptor. Proc. Natl. Acad. Sci. U.S.A. 90, 9954–9958. doi:
10.1073/pnas.90.21.9954
Metzger, T. G., and Ferguson, D. M. (1995). On the role of extracellular loops
of opioid receptors in conferring ligand selectivity. FEBS Lett. 375, 1–4. doi:
10.1016/0014-5793(95)01185-H
Meunier, J. C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvinerie, P., et al.
(1995). Isolation and structure of the endogenous agonist of opioid receptor-
like ORL1 receptor. Nature 377, 532–535. doi: 10.1038/377532a0
Mittal, N., Tan, M., Egbuta, O., Desai, N., Crawford, C., Xie, C. W., et al. (2012).
Evidence that behavioral phenotypes of morphine in beta-arr2-/- mice are due
to the unmasking of JNK signaling. Neuropsychopharmacology 37, 1953–1962.
doi: 10.1038/npp.2012.42
Mohammed, W., Alhaddad, H., Marie, N., Tardy, F., Lamballais, F., Risede,
P., et al. (2013). Comparison of tolerance to morphine-induced respi-
ratory and analgesic effects in mice. Toxicol. Lett. 217, 251–259. doi:
10.1016/j.toxlet.2012.12.021
Molinari, P., Vezzi, V., Sbraccia, M., Grò, C., Riitano, D., Ambrosio, C., et al.
(2010). Morphine-like opiates selectively antagonize receptor-arrestin interac-
tions. J. Biol. Chem. 285, 12522–12535. doi: 10.1074/jbc.M109.059410
Mollereau, C., Parmentier, M., Mailleux, P., Butour, J. L., Moisand, C., Chalon,
P., et al. (1994). ORL1, a novel member of the opioid receptor family.
Cloning, functional expression and localization. FEBS Lett. 341, 33–38. doi:
10.1016/0014-5793(94)80235-1
Morse, M., Sun, H., Tran, E., Levenson, R., and Fang, Y. (2013). Label-free inte-
grative pharmacology on-target of opioid ligands at the opioid receptor family.
BMC Pharmacol. Toxicol. 14:17. doi: 10.1186/2050-6511-14-17
Moulédous, L., Froment, C., Dauvillier, S., Burlet-Schiltz, O., Zajac, J.-M.,
and Mollereau, C. (2012). GRK2 protein-mediated transphosphorylation
contributes to loss of function of μ-opioid receptors induced by neu-
ropeptide FF (NPFF2) receptors. J. Biol. Chem. 287, 12736–12749. doi:
10.1074/jbc.M111.314617
Nakanishi, S., Inoue, A., Kita, T., Nakamura, M., Chang, A. C., Cohen, S. N., et al.
(1979). Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-
lipotropin precursor. Nature 278, 423–427. doi: 10.1038/278423a0
Namir, N., Polastron, J., Allouche, S., Hasbi, A., and Jauzac, P. (1997). The
delta-opioid receptor in SK-N-BE human neuroblastoma cell line undergoes
heterologous desensitization. J. Neurochem. 68, 1764–1772. doi: 10.1046/j.1471-
4159.1997.68041764.x
Navratilova, E., Eaton, M. C., Stropova, D., Varga, E. V., Vanderah, T. W., Roeske,
W. R., et al. (2005). Morphine promotes phosphorylation of the human
delta-opioid receptor at serine 363. Eur. J. Pharmacol. 519, 212–214. doi:
10.1016/j.ejphar.2005.07.024
Navratilova, E., Waite, S., Stropova, D., Eaton, M. C., Alves, I. D., Hruby, V. J., et al.
(2007). Quantitative evaluation of human delta opioid receptor desensitization
using the operational model of drug action. Mol. Pharmacol. 71, 1416–1426.
doi: 10.1124/mol.106.030023
Noble, F., and Cox, B. M. (1996). Differential desensitization of mu- and delta-
opioid receptors in selected neural pathways following chronic morphine
treatment. Br. J. Pharmacol. 117, 161–169. doi: 10.1111/j.1476-5381.1996.
tb15169.x
Nobles, K. N., Xiao, K., Ahn, S., Shukla, A. K., Lam, C. M., Rajagopal, S., et al.
(2011). Distinct phosphorylation sites on the beta(2)-adrenergic receptor estab-
lish a barcode that encodes differential functions of beta-arrestin. Sci. Signal. 4,
ra51. doi: 10.1126/scisignal.2001707
Noda, M., Teranishi, Y., Takahashi, H., Toyosato, M., Notake, M., Nakanishi,
S., et al. (1982). Isolation and structural organization of the human pre-
proenkephalin gene. Nature 297, 431–434. doi: 10.1038/297431a0
Nowoczyn, M., Marie, N., Coulbault, L., Hervault, M., Davis, A., Hanouz, J. L.,
et al. (2013). Remifentanil produces cross-desensitization and tolerance with
morphine on the mu-opioid receptor. Neuropharmacology 73, 368–379. doi:
10.1016/j.neuropharm.2013.06.010
Ong, E. W., and Cahill, C. M. (2014). Molecular perspectives for mu/delta opi-
oid receptor heteromers as distinct, functional receptors. Cells 3, 152–179. doi:
10.3390/cells3010152
Pan, L., Xu, J., Yu, R., Xu, M. M., Pan, Y. X., and Pasternak, G. W. (2005).
Identification and characterization of six new alternatively spliced variants of
the human mu opioid receptor gene, Oprm. Neuroscience 133, 209–220. doi:
10.1016/j.neuroscience.2004.12.033
Pasternak, D. A., Pan, L., Xu, J., Yu, R., Xu, M. M., Pasternak, G. W., et al. (2004).
Identification of three new alternatively spliced variants of the rat mu opioid
receptor gene: dissociation of affinity and efficacy. J. Neurochem. 91, 881–890.
doi: 10.1111/j.1471-4159.2004.02767.x
Pasternak, G. W., and Pan, Y. X. (2013). Mu opioids and their receptors: evolution
of a concept. Pharmacol. Rev. 65, 1257–1317. doi: 10.1124/pr.112.007138
Patierno, S., Anselmi, L., Jaramillo, I., Scott, D., Garcia, R., and Sternini, C. (2011).
Morphine induces mu opioid receptor endocytosis in guinea pig enteric neu-
rons following prolonged receptor activation. Gastroenterology 140, 618–626.
doi: 10.1053/j.gastro.2010.11.005
Pei, G., Kieffer, B. L., Lefkowitz, R. J., and Freedman, N. J. (1995). Agonist-
dependent phosphorylation of the mouse delta-opioid receptor: involvement of
G protein-coupled receptor kinases but not protein kinase C. Mol. Pharmacol.
48, 173–177.
Pert, C. B., and Snyder, S. H. (1973). Opiate receptor: demonstration in nervous
tissue. Science 179, 1011–1014. doi: 10.1126/science.179.4077.1011
Petaja-Repo, U. E., Hogue, M., Laperriere, A., Walker, P., and Bouvier, M. (2000).
Export from the endoplasmic reticulum represents the limiting step in the mat-
uration and cell surface expression of the human delta opioid receptor. J. Biol.
Chem. 275, 13727–13736. doi: 10.1074/jbc.275.18.13727
Petaja-Repo, U. E., Hogue, M., Leskela, T. T., Markkanen, P. M., Tuusa, J. T.,
and Bouvier, M. (2006). Distinct subcellular localization for constitutive and
agonist-modulated palmitoylation of the human delta opioid receptor. J. Biol.
Chem. 281, 15780–15789. doi: 10.1074/jbc.M602267200
Frontiers in Pharmacology | Neuropharmacology December 2014 | Volume 5 | Article 280 | 18
Allouche et al. Opioid receptor desensitization
Pierce, K. L., Premont, R. T., and Lefkowitz, R. J. (2002). Seven-transmembrane
receptors. Nat. Rev. Mol. Cell. Biol. 3, 639–650. doi: 10.1038/nrm908
Polastron, J., Meunier, J. C., and Jauzac, P. (1994). Chronic morphine induces tol-
erance and desensitization of mu-opioid receptor but not down-regulation in
rabbit. Eur. J. Pharmacol. 266, 139–146. doi: 10.1016/0922-4106(94)90103-1
Portoghese, P. S. (1965). A new concept on the mode of interaction of narcotic
analgesics with receptors. J. Med. Chem. 8, 609–616. doi: 10.1021/jm00329a013
Portoghese, P. S., Sultana, M., and Takemori, A. E. (1990). Design of pep-
tidomimetic delta opioid receptor antagonists using the message-address con-
cept. J. Med. Chem. 33, 1714–1720. doi: 10.1021/jm00168a028
Pradhan, A. A., Becker, J. A., Scherrer, G., Tryoen-Toth, P., Filliol, D., Matifas, A.,
et al. (2009). In vivo delta opioid receptor internalization controls behavioral
effects of agonists. PLoS ONE 4:e5425. doi: 10.1371/journal.pone.0005425
Pradhan, A. A., Smith, M. L., Kieffer, B. L., and Evans, C. J. (2012). Ligand-directed
signalling within the opioid receptor family. Br. J. Pharmacol. 167, 960–969. doi:
10.1111/j.1476-5381.2012.02075.x
Pradhan, A. A., Walwyn, W., Nozaki, C., Filliol, D., Erbs, E., Matifas, A.,
et al. (2010). Ligand-directed trafficking of the delta-opioid receptor in vivo:
two paths toward analgesic tolerance. J. Neurosci. 30, 16459–16468. doi:
10.1523/JNEUROSCI.3748-10.2010
Qiu, Y., Law, P. Y., and Loh, H. H. (2003). Mu-opioid receptor desensitization: role
of receptor phosphorylation, internalization, and representation. J. Biol. Chem.
278, 36733–36739. doi: 10.1074/jbc.M305857200
Qiu, Y., Loh, H. H., and Law, P. Y. (2007). Phosphorylation of the delta-opioid
receptor regulates its beta-arrestins selectivity and subsequent receptor inter-
nalization and adenylyl cyclase desensitization. J. Biol. Chem. 282, 22315–22323.
doi: 10.1074/jbc.M611258200
Quillinan, N., Lau, E. K., Virk, M., Von Zastrow, M., and Williams, J. T.
(2011). Recovery from mu-opioid receptor desensitization after chronic treat-
ment with morphine and methadone. J. Neurosci. 31, 4434–4443. doi:
10.1523/JNEUROSCI.4874-10.2011
Quirion, R., Zajac, J. M., Morgat, J. L., and Roques, B. P. (1983). Autoradiographic
distribution of mu and delta opiate receptors in rat brain using highly selec-
tive ligands. Life Sci. 33 (Suppl. 1), 227–230. doi: 10.1016/0024-3205(83)
90484-8
Raehal, K. M., Schmid, C. L., Groer, C. E., and Bohn, L. M. (2011). Functional
selectivity at the mu-opioid receptor: implications for understanding opioid
analgesia and tolerance. Pharmacol. Rev. 63, 1001–1019. doi: 10.1124/pr.111.
004598
Reinscheid, R. K., Nothacker, H. P., Bourson, A., Ardati, A., Henningsen, R. A.,
Bunzow, J. R., et al. (1995). Orphanin FQ: a neuropeptide that activates an
opioidlike G protein-coupled receptor. Science 270, 792–794. doi: 10.1126/sci-
ence.270.5237.792
Rivero, G., Llorente, J., Mcpherson, J., Cooke, A., Mundell, S. J., Mcardle, C. A.,
et al. (2012). Endomorphin-2: a biased agonist at the mu-opioid receptor. Mol.
Pharmacol. 82, 178–188. doi: 10.1124/mol.112.078659
Rostami, A., Rabbani, M., and Mir-Mohammad-Sadeghi, M. (2010). The role of
N53Q mutation on the rat mu-opioid receptor function. J. Biomol. Tech. 21,
92–96.
Schulz, S., Mayer, D., Pfeiffer, M., Stumm, R., Koch, T., and Hollt, V.
(2004). Morphine induces terminal micro-opioid receptor desensitization
by sustained phosphorylation of serine-375. EMBO J. 23, 3282–3289. doi:
10.1038/sj.emboj.7600334
Simon, E. J., Hiller, J. M., and Edelman, I. (1973). Stereospecific binding of the
potent narcotic analgesic (3H) Etorphine to rat-brain homogenate. Proc. Natl.
Acad. Sci. U.S.A. 70, 1947–1949. doi: 10.1073/pnas.70.7.1947
Soignier, R. D., Vaccarino, A. L., Fanti, K. A., Wilson, A. M., and Zadina, J.
E. (2004). Analgesic tolerance and cross-tolerance to i.c.v. endomorphin-1,
endomorphin-2, and morphine in mice. Neurosci. Lett. 366, 211–214. doi:
10.1016/j.neulet.2004.05.046
Song, S. L., and Chueh, S. H. (1999). Phosphorylation promotes the desensitiza-
tion of the opioid-induced Ca2+ increase in NG108-15 cells. Brain Res. 818,
316–325. doi: 10.1016/S0006-8993(98)01216-5
Stafford, K., Gomes, A. B., Shen, J., and Yoburn, B. C. (2001). mu-Opioid receptor
downregulation contributes to opioid tolerance in vivo. Pharmacol. Biochem.
Behav. 69, 233–237. doi: 10.1016/S0091-3057(01)00525-1
Tanowitz, M., and Von Zastrow, M. (2003). A novel endocytic recycling signal that
distinguishes the membrane trafficking of naturally occurring opioid receptors.
J. Biol. Chem. 278, 45978–45986. doi: 10.1074/jbc.M304504200
Tejeda, H. A., Shippenberg, T. S., and Henriksson, R. (2012). The
dynorphin/kappa-opioid receptor system and its role in psychiatric
disorders. Cell. Mol. Life Sci. 69, 857–896. doi: 10.1007/s00018-011-
0844-x
Terenius, L. (1973). Stereospecific interaction between narcotic analgesics and a
synaptic plasm a membrane fraction of rat cerebral cortex. Acta Pharmacol.
Toxicol. (Copenh) 32, 317–320. doi: 10.1111/j.1600-0773.1973.tb01477.x
Terman, G. W., Jin, W., Cheong, Y. P., Lowe, J., Caron, M. G., Lefkowitz, R.
J., et al. (2004). G-protein receptor kinase 3 (GRK3) influences opioid anal-
gesic tolerance but not opioid withdrawal. Br. J. Pharmacol. 141, 55–64. doi:
10.1038/sj.bjp.0705595
Thompson, R. C., Mansour, A., Akil, H., and Watson, S. J. (1993). Cloning and
pharmacological characterization of a rat mu opioid receptor. Neuron 11,
903–913. doi: 10.1016/0896-6273(93)90120-G
Tsao, P. I., and Von Zastrow, M. (2000). Type-specific sorting of G protein-
coupled receptors after endocytosis. J. Biol. Chem. 275, 11130–11140. doi:
10.1074/jbc.275.15.11130
Ueda, H., and Ueda, M. (2009). Mechanisms underlying morphine analgesic tol-
erance and dependence. Front. Biosci. (Landmark Ed.) 14, 5260–5272. doi:
10.2741/3596
Violin, J. D., Crombie, A. L., Soergel, D. G., and Lark, M. W. (2014). Biased ligands
at G-protein-coupled receptors: promise and progress. Trends Pharmacol. Sci.
35, 308–316. doi: 10.1016/j.tips.2014.04.007
Walwyn, W., Evans, C. J., and Hales, T. G. (2007). Beta-arrestin2 and c-Src regu-
late the constitutive activity and recycling of mu opioid receptors in dorsal root
ganglion neurons. J. Neurosci. 27, 5092–5104. doi: 10.1523/JNEUROSCI.1157-
07.2007
Wang, H. L. (2000). A cluster of Ser/Thr residues at the C-terminus of mu-
opioid receptor is required for G protein-coupled receptor kinase 2-mediated
desensitization. Neuropharmacology 39, 353–363. doi: 10.1016/S0028-3908(99)
00174-4
Whistler, J. L., Chuang, H. H., Chu, P., Jan, L. Y., and Von Zastrow, M. (1999).
Functional dissociation of mu opioid receptor signaling and endocytosis: impli-
cations for the biology of opiate tolerance and addiction. Neuron 23, 737–746.
doi: 10.1016/S0896-6273(01)80032-5
Whistler, J. L., Enquist, J., Marley, A., Fong, J., Gladher, F., Tsuruda, P., et al. (2002).
Modulation of postendocytic sorting of G protein-coupled receptors. Science
297, 615–620. doi: 10.1126/science.1073308
Whistler, J. L., and Von Zastrow, M. (1998). Morphine-activated opioid recep-
tors elude desensitization by beta-arrestin. Proc. Natl. Acad. Sci. U.S.A. 95,
9914–9919. doi: 10.1073/pnas.95.17.9914
White, J. M., and Irvine, R. J. (1999). Mechanisms of fatal opioid overdose.
Addiction 94, 961–972. doi: 10.1046/j.1360-0443.1999.9479612.x
Willets, J., and Kelly, E. (2001). Desensitization of endogenously expressed delta-
opioid receptors: no evidence for involvement of G protein-coupled recep-
tor kinase 2. Eur. J. Pharmacol. 431, 133–141. doi: 10.1016/S0014-2999(01)
01360-7
Williams, J. T. (2014). Desensitization of functional micro-opioid recep-
tors increases agonist off-rate. Mol. Pharmacol. 86, 52–61. doi:
10.1124/mol.114.092098
Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., Von Zastrow, M., Schulz,
S., et al. (2013). Regulation of mu-opioid receptors: desensitization, phos-
phorylation, internalization, and tolerance. Pharmacol. Rev. 65, 223–254. doi:
10.1124/pr.112.005942
Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., et al. (2012).
Structure of the human kappa-opioid receptor in complex with JDTic. Nature
485, 327–332. doi: 10.1038/nature10939
Xiang, B., Yu, G. H., Guo, J., Chen, L., Hu, W., Pei, G., et al. (2001). Heterologous
activation of protein kinase C stimulates phosphorylation of delta-opioid
receptor at serine 344, resulting in beta-arrestin- and clathrin-mediated recep-
tor internalization. J. Biol. Chem. 276, 4709–4716. doi: 10.1074/jbc.M00
6187200
Xie,W. Y., He, Y., Yang, Y. R., Li, Y. F., Kang, K., Xing, B.M., et al. (2009). Disruption
of Cdk5-associated phosphorylation of residue threonine-161 of the delta-
opioid receptor: impaired receptor function and attenuated morphine antinoci-
ceptive tolerance. J. Neurosci. 29, 3551–3564. doi: 10.1523/JNEUROSCI.0415-
09.2009
Xu, W., Chen, C., Li, J. G., Dimattio, K., Wang, Y., Unterwald, E., et al. (2013).
PKA and ERK1/2 are involved in dopamine D(1) receptor-induced heterologous
www.frontiersin.org December 2014 | Volume 5 | Article 280 | 19
Allouche et al. Opioid receptor desensitization
desensitization of the delta opioid receptor. Life Sci. 92, 1101–1109. doi:
10.1016/j.lfs.2013.04.006
Yan, Y. H., Wang, Y., Zhao, L. X., Jiang, S., Loh, H. H., Law, P. Y., et al.
(2014). Role of FK506 binding protein 12 in morphine-induced mu-opioid
receptor internalization and desensitization. Neurosci. Lett. 566, 231–235. doi:
10.1016/j.neulet.2014.02.059
Yang, L., Seifert, A., Wu, D., Wang, X., Rankovic, V., Schroder, H., et al. (2010).
Role of phospholipase D2/phosphatidic acid signal transduction in micro-
and delta-opioid receptor endocytosis. Mol. Pharmacol. 78, 105–113. doi:
10.1124/mol.109.063107
Yoon, S. H., Jin, W., Spencer, R. J., Loh, H. H., and Thayer, S. A. (1998).
Desensitization of delta-opioid-induced mobilization of Ca2+ stores in NG108-
15 cells. Brain Res. 802, 9–18. doi: 10.1016/S0006-8993(98)00531-9
Yu, Y., Zhang, L., Yin, X., Sun, H., Uhl, G. R., and Wang, J. B. (1997). Mu opi-
oid receptor phosphorylation, desensitization, and ligand efficacy. J. Biol. Chem.
272, 28869–28874. doi: 10.1074/jbc.272.46.28869
Zhang, J., Ferguson, S. S., Barak, L. S., Bodduluri, S. R., Laporte, S. A., Law, P.
Y., et al. (1998). Role for G protein-coupled receptor kinase in agonist-specific
regulation of mu-opioid receptor responsiveness. Proc. Natl. Acad. Sci. U.S.A.
95, 7157–7162. doi: 10.1073/pnas.95.12.7157
Zhang, L., Loh, H. H., and Law, P. Y. (2013). A novel noncanonical signal-
ing pathway for the mu-opioid receptor. Mol. Pharmacol. 84, 844–853. doi:
10.1124/mol.113.088278
Zhang, L., Zhao, H., Qiu, Y., Loh, H. H., and Law, P.-Y. (2009). Src phos-
phorylation of micro-receptor is responsible for the receptor switching from
an inhibitory to a stimulatory signal. J. Biol. Chem. 284, 1990–2000. doi:
10.1074/jbc.M807971200
Zhang, X., Wang, F., Chen, X., Chen, Y., and Ma, L. (2008). Post-endocytic fates
of delta-opioid receptor are regulated by GRK2-mediated receptor phospho-
rylation and distinct beta-arrestin isoforms. J. Neurochem. 106, 781–792. doi:
10.1111/j.1471-4159.2008.05431.x
Zhang, X., Wang, F., Chen, X., Li, J., Xiang, B., Zhang, Y.-Q., et al.
(2005). Beta-arrestin1 and beta-arrestin2 are differentially required for
phosphorylation-dependent and -independent internalization of delta-
opioid receptors. J. Neurochem. 95, 169–178. doi: 10.1111/j.1471-4159.2005.
03352.x
Zheng, H., Chu, J., Zhang, Y., Loh, H. H., and Law, P. Y. (2011). Modulating
micro-opioid receptor phosphorylation switches agonist-dependent signaling
as reflected in PKCepsilon activation and dendritic spine stability. J. Biol. Chem.
286, 12724–12733. doi: 10.1074/jbc.M110.177089
Zhu, J., Luo, L. Y., Mao, G. F., Ashby, B., and Liu-Chen, L. Y. (1998). Agonist-
induced desensitization and down-regulation of the human kappa opioid
receptor expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 285,
28–36.
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 01 October 2014; accepted: 02 December 2014; published online: 18
December 2014.
Citation: Allouche S, Noble F and Marie N (2014) Opioid receptor desensitization:
mechanisms and its link to tolerance. Front. Pharmacol. 5:280. doi: 10.3389/fphar.
2014.00280
This article was submitted to Neuropharmacology, a section of the journal Frontiers in
Pharmacology.
Copyright © 2014 Allouche, Noble and Marie. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this jour-
nal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | Neuropharmacology December 2014 | Volume 5 | Article 280 | 20
